A Highly Reproducible and Efficient Method for Retinal Organoid Differentiation: Protocols, Optimization, and Applications in Disease Modeling

Abstract

Recent breakthroughs in retinal organoid technology have established highly reproducible and efficient differentiation methods from human pluripotent stem cells, overcoming previous limitations in variability and extended culture times. This article synthesizes current protocols that achieve 100% efficiency in generating pure retinal organoid populations through optimized regulation of BMP signaling and organoid size control. We explore foundational principles of retinal development recapitulation, detailed methodological steps for robust organoid generation, troubleshooting strategies for common challenges, and rigorous validation through molecular profiling and functional assays. For researchers and drug development professionals, this comprehensive review provides an essential resource for implementing these advanced models in high-throughput disease modeling, drug screening, and therapeutic development for conditions like age-related macular degeneration, retinitis pigmentosa, and retinoblastoma.

The Foundation of Retinal Organoids: Recapitulating Human Retinogenesis In Vitro

Retinal organoids (ROs) are three-dimensional, multicellular structures derived from stem cells that mimic the spatial and temporal development of the human retina [1] [2]. The evolution of this technology represents a paradigm shift in ophthalmology research, moving from animal models with inherent species differences and two-dimensional cell cultures lacking tissue architecture to complex, human-specific in vitro systems [3] [1]. This application note traces the key historical milestones in RO development and details the standardized protocols that have emerged to enhance reproducibility for drug discovery and disease modeling applications.

The journey began in 2011 with the pioneering work of Eiraku et al., who demonstrated for the first time that mouse embryonic stem cells could self-organize into optic cup structures in 3D culture [3] [1]. This foundational breakthrough proved that complex retinal tissue could be generated in vitro without the need for exogenous scaffolding, relying instead on the innate self-organization capacity of progenitor cells [1]. Shortly thereafter, in 2012, Nakano's team successfully created optic cup structures from human embryonic stem cells, though with notable differences in development timing and architecture compared to mouse models, highlighting the importance of human-specific systems [1].

These first-generation organoids established the fundamental principle that pluripotent stem cells, when subjected to appropriate signaling cues, could recapitulate key stages of retinogenesis. However, they faced significant limitations in efficiency, reproducibility, and cellular complexity [4] [5]. Early methods often produced organoids with high variability in size, shape, and cellular composition, limiting their utility for standardized applications like drug screening [4]. Furthermore, these initial models lacked essential retinal components such as vascular networks and microglial cells, restricting their ability to fully mimic the in vivo retinal microenvironment [3] [6].

Critical Advancements in Retinal Organoid Technology

Key Historical Milestones

Table 1: Historical Timeline of Retinal Organoid Development

Year	Milestone Achievement	Significance	Reference
2011	First 3D retinal organoids from mouse ESCs	Demonstrated self-organization of stem cells into optic cup structures without scaffolding	[3] [1]
2012	Optic cup generation from human ESCs	Established feasibility of human retinal organoids with species-specific developmental timelines	[1]
2014	Retinal organoids with functional photoreceptors	Advanced organoid functionality by demonstrating phototransduction protein expression	[5]
2020	Single-cell resolution of human retinal cell types	Comprehensive characterization of cellular diversity in retinal organoids	[5]
2024	100% efficiency protocols using standardized aggregation	Solved major reproducibility challenges through controlled initial aggregate formation	[4]
2025	Vascularized retinal organoids with microglial cells	Incorporated vascular networks and immune cells for more physiologically relevant models	[6]

Evolution of Organoid Complexity and Applications

Early retinal organoids primarily contained basic retinal cell types but lacked the organizational maturity and functional capacity of native tissue. The differentiation process was often inefficient, with only a fraction of initial aggregates developing into proper retinal organoids [4]. Through continuous refinement of culture conditions and signaling modulation, researchers achieved progressively more complex organoids containing all major retinal cell types arranged in appropriate layered structures [1] [2].

A significant breakthrough came with the demonstration that organoids could model retinal degenerative diseases using patient-specific induced pluripotent stem cells (iPSCs) [2]. This enabled the study of disease mechanisms in human genetic contexts and opened possibilities for personalized medicine approaches. Further advancements saw the incorporation of retinal pigment epithelium (RPE) cells through co-culture systems, which promoted photoreceptor maturation and enabled more realistic modeling of the retinal environment [3].

The most recent innovations have addressed the historical absence of mesoderm-derived components, particularly vascular networks and microglial cells (the resident immune cells of the retina) [3] [6]. The development of vascularized retinal organoids (vROs) through co-culture with vascular organoids represents a current frontier, enabling the study of neurovascular interactions and barrier function [6]. These advanced models more completely recapitulate the native retinal microenvironment, including characteristics similar to the inner blood-retinal barrier [6].

Current Standards for Highly Reproducible Retinal Organoid Differentiation

Addressing Reproducibility Challenges

Traditional differentiation protocols relying on enzymatic release of hPSC colonies (e.g., using dispase) resulted in high variability in aggregate size and shape, which subsequently affected retinal differentiation efficiency and organoid consistency [4]. This variability posed significant challenges for comparative studies and high-throughput applications. Research revealed that this initial variability in aggregate formation propagated throughout the differentiation process, resulting in organoids with substantially different morphological and cellular characteristics [4].

Modern approaches have addressed these limitations through standardized aggregation techniques that minimize initial variability. The use of forced aggregation in low-adhesion U-bottom plates with defined cell numbers produces uniformly sized aggregates, establishing a consistent starting point for differentiation [4]. This method contrasts with traditional approaches by dissociating hPSC colonies into single-cell suspensions rather than maintaining colony fragments of inconsistent size and composition.

Additional strategies to enhance reproducibility include:

• Agarose microwell arrays to generate homogenously sized embryoid bodies [5]
• V-bottom PDMS microwell platforms that reduce organoid heterogeneity and improve fusion efficiency [6]
• Timed modulation of BMP signaling to direct retinal versus forebrain fate specification with high purity [4]

Table 2: Quantitative Comparison of Traditional vs. Standardized Differentiation Methods

Parameter	Traditional Methods	Standardized Methods	Improvement Significance
Differentiation Efficiency	Variable (line-dependent)	100% across multiple lines	Eliminates batch failures and line dependency issues
Size Variability (Coefficient of Variation)	High (>30%)	Low (<12%)	Enables direct organoid-to-organoid comparisons
Starting Cell Density	Colony fragments of variable size	Defined cells/aggregate (e.g., 2,000 cells)	Controlled initial conditions for predictable outcomes
Retinal Fate Specification	Mixed populations	Pure populations via BMP activation	Reduces contamination with non-retinal cell types
Photoreceptor Maturation Timeline	~150-180 days	Expedited differentiation	Accelerates research timelines and applications

Optimized Signaling Pathways for Retinal Specification

The directed differentiation of pluripotent stem cells into retinal organoids requires precise temporal control of key developmental signaling pathways. The following diagram illustrates the core signaling pathway that guides retinal fate specification in modern protocols:

Diagram 1: Signaling pathway for retinal specification. The timed activation of BMP signaling directs cells toward a retinal fate, while its inhibition results in default forebrain differentiation. Subsequent maturation factors promote photoreceptor development.

Detailed Protocol for Highly Reproducible Retinal Organoid Generation

Initial Aggregate Formation (Days 0-7)

Principle: Establish uniformly sized aggregates through controlled forced aggregation to minimize variability at the critical initial stage [4].

Procedure:

• Culture human pluripotent stem cells (hPSCs) to 70-80% confluence in defined culture system such as Cellartis DEF-CS 500 [5].
• Enzymatically dissociate hPSCs into single-cell suspension using Accutase or similar dissociation reagent.
• Count cells and resuspend at defined density of 2,000 cells/μl in appropriate medium supplemented with ROCK inhibitor (Y-27632, 10 μM).
• Seed 2,000 cells per well in low-adhesion 96-well U-bottom plates. Alternatively, use agarose microwell arrays with 300-600 cells per microwell [5].
• Centrifuge plates at 100 × g for 3 minutes to force aggregate formation.
• Culture for 24 hours, then transfer approximately 45-48 aggregates to 10 cm low-adhesion dishes with gentle agitation every 2-3 days to prevent fusion.
• Transition to neural induction medium (NIM) on day 3, with complete medium changes every other day until day 7.

Critical Parameters:

• Cell density optimization is essential - densities between 1,000-8,000 cells/well yield 100% retinal differentiation efficiency [4]
• Agitation prevents aggregate fusion, which introduces variability
• ROCK inhibitor improves single-cell survival after dissociation

Retinal Specification and Patterning (Days 7-30)

Principle: Apply timed BMP activation to direct neuroepithelial cells toward retinal fate while suppressing alternative neural lineages [4].

Procedure:

• On day 7, transfer embryoid bodies to Matrigel-coated 6-well plates in neural induction medium.
• Culture until day 16, replacing NIM every other day.
• On day 16, transition to '3:1 medium' containing 3 parts DMEM:1 part F12 medium, supplemented with 1% B27 without vitamin A, 1% NEAA, and 1% penicillin/streptomycin [5].
• Between days 28-30, mechanically detach developing retinal structures from the Matrigel using checkerboard scraping.
• Transfer freed retinal structures to low-adhesion plates for suspension culture.

Quality Control Checkpoints:

• By day 10-14: Presence of optic vesicle-like structures with polarized neuroepithelium (ZO-1+ apically, Laminin+ basally) [7]
• By day 28-30: Expression of retinal progenitor markers (RX/RAX+, PAX6+, CHX10/VSX2+) [7]
• Effective retinal specification confirmed by SIX6:GFP reporter expression when using reporter lines [4]

Retinal Maturation and Photoreceptor Differentiation (Days 42-180+)

Principle: Provide sequential maturation signals that promote photoreceptor development and outer segment formation through specific nutrient and signaling factor supplementation.

Procedure:

• From day 42, culture aggregates in 3:1 medium supplemented with 10% heat-inactivated FBS and 100 μM taurine, with media changes every other day [5].
• At week 10, supplement medium with 1 μM retinoic acid to promote photoreceptor maturation.
• From week 14, replace B27 supplement with N2 supplement and reduce retinoic acid to 0.5 μM.
• Continue culture with regular medium changes (3 times per week) for up to 30 weeks for full maturation.

Maturation Markers:

• Week 10-14: Photoreceptor precursors (OTX2+, CRX+) [6] [1]
• Week 14-20: Early photoreceptor markers (Rhodopsin+, Recoverin+) [1]
• Week 20-30: Advanced maturation with outer segment formation and synaptic markers [5]

The following workflow diagram summarizes the complete retinal organoid differentiation process:

Diagram 2: Retinal organoid differentiation workflow. The process begins with standardized aggregation of dissociated hPSCs, proceeds through retinal specification via timed signaling activation, and culminates in mature organoids through extended culture with stage-specific supplements.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Research Reagent Solutions for Retinal Organoid Differentiation

Reagent/Category	Specific Examples	Function in Protocol	Application Notes
Stem Cell Culture System	Cellartis DEF-CS 500 Culture System	Maintenance of undifferentiated hPSCs	Provides defined, xeno-free culture conditions for consistent starting material [5]
Extracellular Matrix	Matrigel, Collagen I	Support for 2D differentiation and organoid fusion	Critical for polarization during optic cup formation; used in VO-RO fusion [6]
Basal Media	DMEM, F12, Neurobasal	Foundation for stage-specific media	3:1 ratio of DMEM:F12 used during key maturation phases [5]
Supplements	B-27, N-2, NEAA	Provide essential nutrients and growth factors	B-27 without vitamin A used initially; transition to N-2 in later stages [5]
Signaling Factors	VEGF-A, FGF-2, Retinoic Acid	Direct vascularization and photoreceptor maturation	VEGF-A (20 ng/ml) promotes vascular network formation in vROs [6]
Metabolic Factors	Taurine, Docosahexaenoic acid (DHA)	Enhance photoreceptor maturation and survival	100 μM taurine significantly improves photoreceptor development [5]
Cell Markers	Anti-arrestin 3, Anti-rhodopsin, Anti-SOX9	Quality assessment of specific retinal cell types	Used for immunofluorescence characterization at different stages [5]
Specialized Equipment	PDMS V-bottom microwell platforms, Agarose micro-molds	Standardized aggregate formation	Significantly reduces size variability compared to traditional methods [4] [6]

The evolution of retinal organoid technology from first-generation models to current standardized protocols represents remarkable progress in ocular regenerative medicine. The development of highly reproducible differentiation methods achieving 100% efficiency marks a critical milestone that enables more reliable disease modeling and drug screening applications [4]. These advances have transformed retinal organoids from specialized research tools into potentially scalable platforms for therapeutic discovery.

Current frontiers continue to address historical limitations, particularly through the creation of vascularized retinal organoids containing microglial cells [6]. These advanced models more completely recapitulate the native retinal microenvironment, including functional characteristics similar to the inner blood-retinal barrier [6]. The incorporation of immune cells enables study of neuroinflammatory components in retinal diseases, while vascular networks address nutrient diffusion limitations in larger organoids.

Future directions will likely focus on further enhancing physiological relevance through:

• Integration of multiple ocular cell types (RPE, vascular, immune) in spatially appropriate organizations
• Functional connectivity models between retinal organoids and brain visual centers
• Standardized quality metrics and benchmarking across laboratories
• Automated, high-throughput production systems for drug screening applications
• Pre-clinical applications for cell replacement therapies using organoid-derived photoreceptors [7]

As standardization improves and protocols become more widely adopted, retinal organoids are poised to become indispensable tools for understanding human retinal development, disease mechanisms, and therapeutic development. The historical progression from variable, simple structures to reproducible, complex retinal models illustrates how methodological refinements have steadily enhanced the physiological relevance and practical utility of these innovative systems.

The process of retinal organoid differentiation represents a landmark achievement in regenerative medicine, harnessing the innate, tissue-autonomous self-organization principles that guide embryonic eye development [8]. In vivo, the optic cup forms from the anterior neural plate through a precisely orchestrated sequence of morphogenetic events involving evagination, invagination, and cell fate specification [9] [10]. The groundbreaking discovery that pluripotent stem cell (PSC) aggregates can spontaneously undergo similar patterning in three-dimensional (3D) culture to form optic vesicle and optic cup structures has provided a powerful model system [11] [8]. This process is governed by a spatiotemporal cascade of transcription factors and signaling molecules that drive the emergence of a complex, laminated neural tissue from a seemingly homogeneous cell population [9]. This Application Note details the protocols and mechanistic insights essential for achieving highly reproducible retinal organoid differentiation, framing them within the context of self-organization principles for an audience of researchers and drug development professionals.

Theoretical Foundations: The Self-Organizing Retina

Key Developmental Signaling Pathways

The self-organization of the optic cup from stem cell aggregates is not a pre-programmed script but an emergent property resulting from the interaction of specific signaling pathways. These pathways establish domains of neural retina and retinal pigment epithelium (RPE) fates within the developing optic vesicle [8] [10]. The timely and spatially controlled activation and inhibition of these pathways are critical for correct patterning.

Table 1: Key Signaling Pathways in Optic Cup Patterning

Pathway	Primary Role in Optic Cup Development	Common Modulators in Culture
BMP	Critical for neural induction and optic vesicle patterning; promotes retinal fate [12] [10].	BMP4; used in defined concentrations to specify neuroepithelium and achieve pure retinal organoid populations [12].
TGF-β/Activin A	Involved in the specification of the RPE lineage from the outer layer of the optic cup [10].	Often added in combination with other factors to induce RPE differentiation.
FGF	Promotes neural retina identity over RPE fate within the bipotent optic vesicle [8] [10].	FGF1, FGF2; typically supplemented during the initial stages of neural induction.
Wnt	Regulates dorsal-ventral patterning; its inhibition is often necessary for primary retinal specification [8].	Small molecule inhibitors such as IWR-1 or Dkk1 are used to promote retinal progenitor identity.
Shh	Contributes to the ventral patterning of the optic cup and the formation of the optic stalk [10].	Agonists (e.g., Purmorphamine) or antagonists (e.g., Cyclopamine) can be used to modulate ventral identities.

The Cellular Competence Model

A fundamental concept underlying retinal histogenesis is the "competence model," which is faithfully recapitulated in retinal organoids [9]. This model posits that retinal progenitor cells (RPCs) are multipotent but undergo sequential changes in their competence (potency) to produce different cell types over time. The sequential order of retinal cell generation is highly conserved: retinal ganglion cells are born first, followed by cone photoreceptors, horizontal cells, and amacrine cells, and finally rod photoreceptors, bipolar cells, and Müller glia [9] [8]. This intrinsic timing mechanism, regulated by a dynamic network of transcription factors, ensures the proper layering of the retina, a process that organoids can mimic with high fidelity in the absence of external cues [9].

Figure 1: Signaling Logic in Self-Organization. This workflow outlines the key stages and signaling pathways from stem cell aggregate to a layered neural retina.

Experimental Protocols for Highly Reproducible Retinal Organoid Differentiation

Recent methodological advances have addressed critical limitations in the efficiency and reproducibility of retinal organoid generation. The following protocol, standardized from prior methods, leverages regulation of organoid size and timed BMP activation to achieve 100% efficiency in retinal organoid formation from multiple widely used hPSC lines [12].

Core Differentiation Workflow

Table 2: Protocol for Highly Efficient Retinal Organoid Differentiation

Stage	Process	Key Media Components / Actions	Duration	Expected Outcome
1. Aggregation	Formation of uniform embryoid bodies (EBs).	Dissociate hPSCs to single cells. Seed in V-bottom 96-well plates (~3,000-9,000 cells/well) in EB medium with Rock inhibitor [12] [13].	1-2 days	Formation of evenly sized, spherical EBs.
2. Neural Induction	Specification of neuroepithelium and optic vesicle (OV) formation.	Culture in neural induction medium containing BMP4 to direct retinal fate [12]. Inhibiting BMP signals instead directs forebrain fate [12].	~6-10 days	Emergence of translucent, neuroepithelial out-pockets (OV-like structures).
3. Optic Cup Formation	Self-organization of OVs into bilayered neural retina and RPE domains.	Mechanically isolate OV structures and transfer to suspension culture in retinal differentiation medium [11] [8].	From day ~18	Invagination of OVs to form pigmented, cup-shaped structures.
4. Retinal Maturation & Lamination	Differentiation of all major retinal cell types and formation of nuclear and plexiform layers.	Long-term culture in maturation media with Taurine, Retinoic Acid, and B27 supplement [11].	Up to 38+ weeks	Formation of a stratified organoid with distinct ONL, INL, and IPL, and light-responsive photoreceptors [14].

Critical Factors for Enhancing Reproducibility

• Initial Aggregate Size and Shape: Standardizing the initial number of cells per aggregate using V-bottom or low-adhesion 96-well plates is crucial for minimizing variability and ensuring synchronous development [12] [13].
• Timed BMP Signaling Activation: The precise application of BMP4 during the neural induction stage is a key determinant. This study demonstrated that timed BMP activation is necessary and sufficient to generate pure populations of retinal organoids, while its inhibition completely diverts cells to a forebrain fate [12].
• Line-Specific Optimization: While the protocol is robust across multiple lines, researchers should be prepared for minor, line-specific adjustments in cell seeding density and growth factor concentration to achieve optimal results [8].

The Scientist's Toolkit: Essential Research Reagents

The following table details key reagents and their functional roles in establishing a robust retinal organoid differentiation protocol.

Table 3: Key Research Reagent Solutions for Retinal Organoid Differentiation

Reagent / Material	Function	Application Note
Human Pluripotent Stem Cells (hPSCs)	Starting cellular material. Includes both ESCs and iPSCs.	iPSCs allow for patient-specific disease modeling [11] [13]. Maintain high-quality, karyotypically normal cultures.
BMP4 (Recombinant Human)	A morphogen that directs retinal fate from hPSC-derived progenitors.	The timed addition of BMP4 is critical for achieving 100% efficiency in retinal organoid induction [12].
Rock Inhibitor (Y-27632)	Enhances survival of single hPSCs during passaging and aggregation.	Used in the aggregation medium to prevent anoikis and improve EB formation efficiency [13].
Matrigel / Basement Membrane Extract	Provides a 3D extracellular matrix environment that supports epithelial integrity and morphogenesis.	Used in some protocols to embed aggregates for initial stages [15] [13].
Retinoic Acid	A small molecule that promotes photoreceptor maturation and outer segment development.	Added during the prolonged maturation phase [11].
Taurine	An amino acid that supports photoreceptor survival and function.	A standard component of retinal maturation media [11].
Noggin (BMP Inhibitor)	Suppresses BMP signaling.	Can be used to confirm retinal vs. forebrain fate specification, as inhibition of BMP directs cells to a forebrain identity [12].

Application in Disease Modeling and Drug Development

Retinal organoids that faithfully mimic the self-organization of the native retina have become a next-generation platform for biomedical research. Their most significant application lies in modeling inherited retinal diseases (IRDs) such as retinitis pigmentosa, for which over 90 associated genes have been identified [11]. By generating organoids from patient-derived iPSCs, researchers can study disease mechanisms in a human genetic background, clarifying the cell-type-specific expression of disease-associated genes and investigating pathological changes at the molecular, cellular, and structural levels [14].

Furthermore, the field is moving towards high-throughput drug discovery using retinal organoids [13]. While technical challenges related to 3D culture screening remain, organoids provide a human-relevant system for evaluating drug efficacy and toxicity, bypassing the species differences inherent in animal models. The integration of organoids with technologies like microfluidic organ-on-a-chip platforms and 3D bioprinting is poised to further enhance their utility and reproducibility for large-scale pharmaceutical screening [13].

The self-organization of the retina, from a simple neuroepithelium to a complex, layered sensory tissue, is a remarkable process that can be harnessed in vitro. The protocols and principles outlined herein provide a roadmap for achieving highly reproducible and efficient retinal organoid differentiation. By meticulously controlling initial conditions, such as aggregate size, and leveraging key signaling pathways, specifically timed BMP activation, researchers can generate robust in vitro models that recapitulate human retinogenesis. These organoids are an indispensable tool for deconstructing developmental mechanisms, modeling diseases in a human context, and accelerating the development of novel therapies for blinding retinal conditions.

Key Developmental Markers and Staging Systems for Quality Assessment

The emergence of three-dimensional retinal organoid technology has revolutionized the study of human retinogenesis, disease modeling, and drug development. These self-organizing structures, derived from human pluripotent stem cells (hPSCs), closely mimic the spatial and temporal patterning of the developing human retina [16]. However, the inherent variability in differentiation efficiency and cellular composition across protocols and cell lines necessitates robust quality assessment frameworks. A standardized approach to staging retinal organoids based on morphological and molecular markers provides an essential tool for ensuring reproducibility, enabling meaningful cross-study comparisons, and validating the maturity of these complex in vitro models [17] [18]. This application note details the key developmental markers and staging systems indispensable for the quality assessment of retinal organoids within a rigorous research environment.

Key Developmental Markers of Retinal Organoids

The progression of retinal organoids from pluripotent stem cells to structured neural retina parallels in vivo human retinogenesis, characterized by the sequential expression of specific molecular markers. The following table summarizes the key proteins used to identify major retinal cell types and assess organoid maturation.

Table 1: Key Immunohistochemical Markers for Retinal Cell Types in Organoids

Retinal Cell Type	Key Markers	Expression and Localization Notes
Photoreceptor Precursors	CRX [19] [20]	Photoreceptor-specific transcription factor; early precursor marker.
Rod Photoreceptors	NRL [20], Rhodopsin [2] [20]	NRL is an early rod-specific marker; Rhodopsin is a mature rod opsin.
Cone Photoreceptors	Recoverin [2] [20], L/M/S-Opsins [20]	Recoverin is expressed in cones; Opsins define cone subtypes.
Retinal Ganglion Cells (RGCs)	BRN3A [19] [17], PAX6 [2], Calretinin [2]	RGC-specific transcription factors and proteins; among first cells to differentiate.
Müller Glia	CRALBP [2] [17]	Expressed in Müller glial cells, which provide structural support.
General Neuronal & Synaptic	VSX2 [20], Synaptophysin [20]	VSX2 marks retinal progenitor cells; Synaptophysin labels synaptic vesicles.

The differentiation timeline follows a predictable pattern. Retinal ganglion cells (RGCs) are the first to appear, expressing markers like BRN3A and PAX6 around differentiation day 40-50 [17] [20]. This is followed by the emergence of cone and rod photoreceptor precursors, marked by CRX expression [19]. Over time, these precursors mature, expressing cell-type-specific opsins such as Rhodopsin in rods [20]. A critical indicator of advanced photoreceptor maturation is the formation of outer segments, which can be visualized by electron microscopy and are associated with the expression of proteins involved in the connecting cilium and phototransduction cascade [2] [18]. The presence of a distinct outer limiting membrane, formed by Müller glia end-feet, is another hallmark of advanced organization [17].

Established Staging Systems for Retinal Organoids

To reduce inconsistencies and increase rigor, a practical morphological staging system has been developed, which complements the use of elapsed differentiation time [17]. This system is based on easily discernible features observable by light microscopy and optical coherence tomography in live cultures.

Diagram 1: Morphological staging timeline for retinal organoids.

Stage 1: Early Differentiation and Retinal Ganglion Cell Genesis

Time Frame: Approximately differentiation day 30 to 50 [17] [20]. Morphology: Organoids exhibit a continuous, well-defined, and phase-bright outer neuroepithelial rim [17]. This rim is populated by neuroretinal progenitor cells (NRPCs) [2]. Cellular Composition: The inner part of the organoid harbors numerous retinal ganglion cells (RGCs), which are the first retinal cell type to undergo differentiation [2] [20]. A rudimentary inner plexiform-like layer may also be present [17]. Key Markers: PAX6, VSX2 (progenitors); BRN3A, Calretinin (RGCs) [2] [19].

Stage 2: Transition and Photoreceptor Progenitor Emergence

Time Frame: Approximately differentiation day 80 to 120 [17] [20]. Morphology: The organoids develop a phase-dark core, and the previously prominent bright outer rim diminishes [2] [20]. Cellular Composition: This stage represents a transition. The discrete RGC layer gradually deteriorates, seemingly due to the lack of connection to brain targets [17] [20]. Concurrently, neural retina progenitors undergo progressive differentiation into early progenitors of cone and rod photoreceptors [2]. Horizontal and amacrine cells also become more prominent [17]. Key Markers: CRX (photoreceptor precursors) [19].

Stage 3: Photoreceptor Maturation and Lamination

Time Frame: Approximately differentiation day 120 to 180 and beyond [17] [20]. Morphology: The outer rim becomes more prominent again and develops hair-like or brush-border-like structures corresponding to the photoreceptor inner and outer segments [20] [18]. The organoid displays clear lamination resembling the native retina. Cellular Composition: This stage is marked by the enhancement of photoreceptor structures and continued maturation [2]. Rod and cone photoreceptors express mature markers and develop outer segments. Bipolar cells and Müller glia are generated, while inner retinal cell types may become disorganized over time [17]. Key Markers: Rhodopsin (rods), Recoverin and L/M/S-Opsins (cones), CRALBP (Müller glia) [2] [20].

Table 2: Morphological and Molecular Characteristics of Retinal Organoid Stages

Stage	Time Period (Days)	Key Morphological Features	Primary Cellular Events
Stage 1	~30 - 50	Phase-bright outer neuroepithelial rim [17].	Differentiation of retinal ganglion cells and early progenitors [2] [20].
Stage 2	~80 - 120	Phase-dark core; reduced bright rim [2].	Decline of RGCs; emergence of photoreceptor precursors [17].
Stage 3	~120 - 180+	Visible outer rim with hair-like structures (inner/outer segments) [20].	Maturation of photoreceptors with outer segment formation; lamination [18].

Experimental Protocol for Staging and Marker Analysis

This protocol outlines the key steps for the differentiation, collection, and quality assessment of retinal organoids, focusing on morphological staging and immunohistochemical validation.

Diagram 2: Retinal organoid differentiation and quality assessment workflow.

Retinal Organoid Differentiation

The following methodology is a synthesis of established protocols, incorporating elements that enhance reproducibility and yield [19] [17] [18].

• Maintenance of hPSCs: Culture human iPSCs in defined media (e.g., mTeSR Plus or StemFit) on plates coated with hESC-qualified Matrigel or Laminin-511-E8 [19] [18]. Maintain cells in a dense colony state and passage regularly.
• Initiation of Differentiation (Day 0):
  • Adapt the base medium to Glasgow's Minimum Essential Medium (GMEM) supplemented with 10% KnockOut Serum Replacement (KSR), 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 450 µM 1-monothioglycerol [18].
  • To significantly improve retinal domain yield, add 3 nM Bone Morphogenetic Protein 4 (BMP4) from day 1 to day 3 of differentiation [19] [17]. This treatment has been shown to increase the self-formation of neuroretinal epithelia.
• Formation and Isolation of Retinal Domains (Day ~10-30):
  • Tightly packed retinal clusters will form at the bottom of the culture dish. Between days 10 and 30, manually excise these distinct, phase-bright retinal domains using fine forceps or cannulas under a dissecting microscope [19] [21].
  • Transfer the isolated domains to ultra-low attachment plates for suspension culture.
• Long-Term Suspension Culture and Maturation (Day 30+):
  • Culture the organoids in retinal maturation media, typically based on DMEM/F12 or Advanced DMEM/F12, supplemented with components such as N2 and B27 supplements, 10% Fetal Bovine Serum (FBS), 100 µM Taurine, and 1 µM all-trans Retinoic Acid (RA) [21] [18].
  • To promote photoreceptor differentiation and survival, some protocols include a Hedgehog pathway agonist like 100 nM Smoothened Agonist (SAG) [19].
  • Change half of the medium every 2-3 days. Culture organoids for extended periods (up to 200 days or more) to achieve advanced maturation [19] [17].

Quality Assessment and Staging Methodologies

• Live Morphological Staging:

  • Procedure: Weekly, observe live organoids using an inverted phase-contrast microscope. Document their overall morphology, the appearance of the outer rim, and the presence of any dark cores or hair-like protrusions [17].
  • Application: Classify each organoid into a developmental stage (1, 2, or 3) based on the criteria outlined in Section 3 and Table 2. This allows for the selection of age- and stage-matched organoids for experiments, reducing variability.

• Immunohistochemical Validation:

  • Sample Preparation: Fix organoids in 4% Paraformaldehyde (PFA) at 4°C overnight. Cryoprotect by immersing in 15% and then 30% sucrose before embedding in O.C.T. compound and cryosectioning (10 µm thickness) [21] [18].
  • Staining:
    • Perform antigen retrieval on frozen sections using citrate buffer (pH 6.0) at 95°C for 30 minutes [21].
    • Block sections with 5% normal donkey or goat serum with 0.1-0.5% Triton X-100 for 1 hour at room temperature.
    • Incubate with primary antibodies (see Table 1) diluted in blocking solution overnight at 4°C.
    • The next day, incubate with appropriate Alexa Fluor-conjugated secondary antibodies for 1-2 hours at room temperature. Counterstain nuclei with DAPI and mount slides.
  • Imaging and Analysis: Acquire images using a confocal laser scanning microscope. Use Z-stack imaging and 3D reconstruction software to assess the spatial distribution of cells and the overall tissue architecture within the organoid [21].

The Scientist's Toolkit: Essential Research Reagents

The following table details key reagents and their critical functions in retinal organoid differentiation and analysis.

Table 3: Essential Research Reagents for Retinal Organoid Differentiation and Analysis

Reagent Category	Specific Example	Function in Differentiation/Assay
Small Molecule Inducers	BMP4 (Bone Morphogenetic Protein 4) [19] [17] [18]	Directs cells toward retinal fate; increases yield of retinal domains.
Small Molecule Inducers	SAG (Smoothened Agonist) [19]	Activates Hedgehog signaling; enhances survival of neural cells.
Small Molecule Inducers	DAPT (Notch Inhibitor) [19]	Inhibits Notch signaling; increases photoreceptor yield.
Differentiation Media Supplements	All-trans Retinoic Acid (RA) [19] [21]	Promotes rod photoreceptor differentiation and maturation.
Differentiation Media Supplements	Taurine [21]	Supports photoreceptor development and survival.
Basal Media	KnockOut Serum Replacement (KSR) [21] [18]	Used in early differentiation to support cell growth and specification.
Basal Media	B-27 & N-2 Supplements [19] [18]	Chemically defined supplements providing hormones, lipids, and proteins for neuronal and retinal cell health.
Extracellular Matrix	Matrigel [19] [21]	Provides a basement membrane matrix to support 3D cell growth and polarization.
Fixative	Paraformaldehyde (PFA) [21] [18]	Cross-links proteins to preserve cellular morphology for immunohistochemistry.

The adoption of a standardized framework for assessing retinal organoids, based on well-defined morphological stages and validated by key molecular markers, is fundamental for achieving rigor and reproducibility in research. The staging system and analytical protocols detailed in this application note provide a practical roadmap for scientists to reliably quality-check their cultures, trace their developmental progression, and generate high-quality, consistent data. As the field advances, with protocols yielding organoids featuring more mature structures like budding calyceal processes [18], these foundational quality assessment principles will remain paramount for validating new models and translating retinal organoid technology into robust drug discovery and therapeutic applications.

Structural and Functional Benchmarking Against Native Retinal Tissue

Retinal organoids (ROs) derived from human pluripotent stem cells (hPSCs) have emerged as a transformative in vitro platform for studying human retinogenesis, disease modeling, and drug screening [11] [10]. These three-dimensional, self-organizing structures recapitulate the complex cellular diversity and layered architecture of the native human retina, offering a powerful alternative to traditional animal models, which often fail to fully simulate human clinical phenotypes [11]. A critical step in validating these models for preclinical research is rigorous structural and functional benchmarking against native retinal tissue. This application note details standardized methodologies and quantitative benchmarks for evaluating the maturation and fidelity of retinal organoids, providing a framework for researchers to assess the physiological relevance of their models within the context of highly reproducible differentiation protocols.

Structural Benchmarking of Retinal Organoids

Recapitulation of Retinal Histoarchitecture

A defining feature of a high-quality retinal organoid is its ability to self-organize into the distinct laminated layers observed in vivo. The native neural retina comprises three nuclear layers: the outer nuclear layer (ONL) containing photoreceptor nuclei, the inner nuclear layer (INL) housing bipolar, horizontal, amacrine, and Müller glial cells, and the ganglion cell layer (GCL) [11]. These are interspersed with two plexiform layers (OPL and IPL) where synaptic connections occur [11].

Assessment Protocol: Immunohistochemical Analysis of Layering

• Fixation: Collect ROs at desired timepoints (e.g., D100, D150) and fix in 4% paraformaldehyde for 30 minutes at 4°C [18].
• Cryopreservation and Sectioning: Immerse ROs in a sucrose gradient (e.g., 6.12%, 12.5%, 25%) for cryoprotection, embed in O.C.T. compound, and section at 10 μm thickness using a cryostat [18] [22].
• Staining: Perform immunofluorescence staining with a panel of cell-type-specific antibodies after blocking with 5% serum and 0.05% Triton X-100. Counterstain nuclei with DAPI [18].
• Imaging: Acquire high-resolution images using confocal laser scanning microscopy to visualize the spatial organization of different cell types [18].

Table 1: Key Molecular Markers for Structural Benchmarking of Retinal Organoids

Cellular Component	Key Marker	Expression Timeline in ROs	Native Tissue Correlation
Photoreceptors	CRX (Transcription factor)	Present by ~D100 [11]	ONL [11]
	RHO (Rhodopsin)	Increases by ~D150 [11]	Rod Outer Segments [11]
	OPSIN (e.g., S/OPSIN)	Increases by ~D150 [11]	Cone Outer Segments [11]
Bipolar Cells	VSX2 (Transcription factor)	Low at D100 [11]	INL [11]
	PKCα (Protein Kinase C alpha)	Visible by D150 [11]	INL (Rod Bipolar Cells) [11]
Ganglion Cells	BRN3A (Transcription factor)	High at D100 [11]	GCL [11]
	RBPMS (RNA-Binding Protein)	Decreases by D150 [11]	GCL [11]
Amacrine Cells	CALB2 (Calretinin)	Consistent expression D100-D150 [11]	INL [11]
	PAX6 (Transcription factor)	Consistent expression D100-D150 [11]	INL [11]
Müller Glia	SOX9 (Transcription factor)	Upregulated by D150 [11]	Spanning all layers [11]
	GFAP (Glial Fibrillary Acidic Protein)	Low at D100 [11]	Activated state [11]
Horizontal Cells	PROX1 (Transcription factor)	Moderate at D100 [11]	INL [11]
	AP2α (Transcription Factor AP-2 alpha)	Clear expression at D150 [11]	INL [11]

Ultrastructural Maturation of Photoreceptors

The development of inner segments (IS) and outer segments (OS) with stacked disk membranes is a hallmark of photoreceptor maturity. The outer segment is a modified cilium packed with light-sensitive opsin proteins, while the inner segment contains mitochondria and biosynthetic machinery [18]. In primates, photoreceptors also develop calyceal processes, microvilli-like structures that extend from the inner segment and surround the base of the outer segment, providing structural stability [18].

Assessment Protocol: Transmission Electron Microscopy (TEM)

• Primary Fixation: Fix ROs in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer for several hours at 4°C.
• Secondary Fixation: Post-fix in 1% osmium tetroxide for 1-2 hours.
• Dehydration and Embedding: Dehydrate through a graded ethanol series and embed in epoxy resin.
• Sectioning and Staining: Cut ultrathin sections (60-90 nm), stain with uranyl acetate and lead citrate.
• Imaging: Image using a TEM to identify connecting cilia, inner/outer segments, disk membrane formation, and budding calyceal processes [18].

Advanced protocols have demonstrated that optimized culture conditions, including antioxidant and lipid supplementation, can promote the formation of these intricate structures within 140 days, including budding calyceal process-like structures and the localization of Usher syndrome proteins, which are critical for periciliary function [18].

Functional Benchmarking of Retinal Organoids

Photoreceptor Function and Light Responsiveness

Functional maturity is demonstrated by the organoid's ability to recapitulate the phototransduction cascade, the biochemical pathway that converts light into an electrical signal.

Assessment Protocol: Calcium Imaging for Light Response

• Dye Loading: Incubate intact or sectioned ROs with a calcium-sensitive fluorescent dye (e.g., Fluo-4 AM) in the culture medium for 30-60 minutes at 37°C.
• Stimulation and Imaging: Transfer ROs to a recording chamber. Use a fluorescence microscope equipped with a light source capable of delivering defined light flashes (specific wavelengths and intensities). Monitor fluorescence changes in photoreceptors in response to light flashes.
• Analysis: A measurable decrease in intracellular calcium levels in photoreceptors upon light stimulation indicates a physiological light response, as phototransduction cascade activation leads to hyperpolarization [11] [10].

Assessment Protocol: Electrophysiology

• Patch Clamp Recording: Use micropipettes to achieve a high-resistance seal (giga-ohm seal) on individual photoreceptors in sliced or whole-mount ROs.
• Stimulation: Record membrane currents (voltage-clamp) or potentials (current-clamp) in response to light stimuli.
• Validation: Mature photoreceptors should exhibit characteristic light-sensitive currents, including the closure of cGMP-gated channels in the outer segment upon light exposure [10].

Table 2: Quantitative Functional Benchmarks for Retinal Organoids

Functional Parameter	Assessment Method	Benchmark in Mature Native Tissue	Representative Achievement in Advanced ROs
Light-Induced Response	Calcium Imaging	Decreased Ca²⁺ in photoreceptors [11]	Demonstrated in ROs [11] [10]
Photoreceptor Electrophysiology	Patch Clamp Recording	Characteristic light-sensitive currents [10]	Expected in mature RO photoreceptors [10]
Synaptic Connectivity	Immunostaining for Pre-/Post-synaptic Markers	Colocalization of markers in plexiform layers [23]	Presence of pre-synaptic markers in PRs adjacent to bipolar cell dendrites [23]
Opsin Expression & Localization	Immunostaining / Western Blot	Robust, compartmentalized to OS [18]	Compartmentalized architecture with distinct IS/OS [18]
Outer Segment Disk Formation	Transmission Electron Microscopy	Hundreds of stacked, enclosed disks [18]	Formation of disk membranes and ciliary structures [18]

Synaptic Connectivity and Network Function

The formation of functional synapses in the outer and inner plexiform layers is essential for transmitting visual information from photoreceptors to bipolar and ganglion cells.

Assessment Protocol: Synaptic Marker Colocalization

• Utilize immunohistochemistry on retinal organoid sections with antibodies against pre-synaptic markers (e.g., RIBEYE, SV2) found in photoreceptor and bipolar cell terminals, and post-synaptic markers (e.g., mGluR6 for ON-bipolar cells) [23].
• Analyze using confocal microscopy to confirm the close apposition of pre- and post-synaptic signals in the plexiform layers, indicating potential synaptic sites. Studies on porcine iPSC-derived ROs have shown the presence of pre-synaptic markers in photoreceptor axon terminals adjacent to the dendritic terminals of bipolar cells, suggesting synaptic pairing [23].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Retinal Organoid Generation and Benchmarking

Reagent / Material	Function / Role	Example
hiPSC/ hESC Lines	Starting cell source for generating patient-specific or control organoids.	hiPSC line 1231A3 (Kyoto University); AD lines (e.g., UCSD239i-APP2-1) for disease modeling [18] [22].
Basement Membrane Matrix	Provides a substrate for initial pluripotent stem cell culture and embryoid body plating.	Growth factor-reduced Matrigel [22].
BMP4	Morphogen used in early differentiation to direct cells toward retinal fate.	3 nM, added during the first 3 days of differentiation [18] [16].
Smoothened Agonist (SAG)	Activator of the Sonic Hedgehog pathway, crucial for eye field patterning and growth.	100 nM, added from day 10 [18].
All-trans Retinoic Acid (RA)	Signaling molecule promoting photoreceptor differentiation and maturation.	1 μM, typically added after day 60 [18].
B27 & N2 Supplements	Serum-free supplements providing essential hormones, proteins, and lipids for neural and retinal cell survival and growth.	Used in various concentrations in differentiation and maturation media [18] [22].
Taurine	Amino acid that supports photoreceptor health and development.	100 μM, included in maturation media [18] [22].
Antibody Panels	Critical tools for immunostaining-based structural benchmarking.	Antibodies against CRX, RHO, OPSIN, PKCα, BRN3A, CALB2, SOX9, etc. [11] [18].

Experimental Workflow & Signaling Pathways

The generation and benchmarking of retinal organoids follow a multi-stage process, from pluripotent stem cell to a mature, laminated tissue. The following workflow diagram outlines the key steps and temporal progression.

The differentiation process is controlled by the timed manipulation of key evolutionary conserved signaling pathways that govern embryonic eye development. The following diagram summarizes the critical pathways and their modifiers.

Applications in Disease Modeling and Drug Screening

Robustly benchmarked retinal organoids are a powerful tool for modeling human retinal diseases. For example, ROs generated from induced pluripotent stem cells (iPSCs) of patients with Familial Alzheimer's Disease (FAD) carrying mutations in the Amyloid Precursor Protein (APP) gene successfully recapitulated key disease pathologies, including increased levels of Amyloid-β (Aβ) and phosphorylated Tau (pTau), providing a new model for drug screening and pathophysiological studies [22]. Furthermore, ROs can model inherited retinal diseases (IRDs) like Usher syndrome, where the localization of Usher proteins to the periciliary region of photoreceptors can be studied [18]. The ability to source organoids from specific patient populations enables the development of personalized therapeutic screening platforms, bridging a critical gap between animal models and human clinical trials [24] [22].

Optimized Protocols for Highly Reproducible Retinal Organoid Generation

The differentiation of pluripotent stem cells into retinal organoids represents a powerful in vitro model for studying human retinogenesis, disease modeling, and drug screening. A significant challenge in this field has been the extended timeframe required to generate mature retinal organoids with structurally defined photoreceptors. Recent research has demonstrated that the precise pharmacological modulation of key developmental signaling pathways—Bone Morphogenetic Protein (BMP), Sonic Hedgehog (SHH), Activin A, and Retinoic Acid (RA)—can dramatically accelerate retinal organoid maturation while improving morphological fidelity and cellular specification. This Application Note details optimized protocols leveraging these signaling pathways to achieve advanced retinal organoid maturation within significantly reduced timeframes, enhancing the reproducibility and throughput of retinal disease modeling and therapeutic screening applications.

Pathway Mechanisms and Experimental Evidence

Core Signaling Pathways in Retinal Development

The coordinated interplay of BMP, SHH, Activin A, and Retinoic Acid signaling is critical for proper retinal patterning, photoreceptor specification, and structural maturation. The molecular mechanisms of these pathways and their experimental manipulation are summarized below.

Table 1: Core Signaling Pathways in Retinal Organoid Differentiation

Pathway	Key Components	Role in Retinogenesis	Experimental Modulation
BMP Signaling	BMP4, BMPR1A/B, BMPR2, SMAD1/5/9 [25] [26]	Directs PSCs toward retinal fate; regulates neuroblastoma cell fate and RA sensitivity [27] [26]	Initial BMP4 treatment (DD1-DD3) for neural retinal induction [27]
Sonic Hedgehog (SHH)	Shh ligand, Patched (Ptch), Smoothened (Smo), Gli transcription factors [28] [29]	Promotes retinal cell specification, maturation, and lamination; regulates neuroprotection [27] [28]	SAG (Smoothened agonist) treatment from DD10 onward [27]
Activin A	Activin A, SMAD2/3	Supports rapid retinal cell specification and differentiation [27]	Combined with SAG and RA from DD10 to DD40 [27]
Retinoic Acid (RA)	Retinoic acid receptors (RAR, RXR), CYP26A1 [30] [26]	Critical for photoreceptor maturation and cone subtype specification [30] [26]	All-trans RA from DD10 to DD40; timing crucial for cell cycle exit and cone specification [27] [30]

Figure 1: Signaling Pathways in Retinal Organoid Differentiation. The core pathways—BMP, SHH, and Retinoic Acid—act in coordination to direct retinal fate specification, cell differentiation, and structural maturation. BMP signaling initiates retinal induction, SHH promotes specification and lamination, and RA drives photoreceptor maturation, with CYP26A1 providing critical temporal regulation through RA catabolism.

Key Experimental Findings

Functional studies demonstrate that BMP signaling is essential for early retinal induction, with BMP4 treatment during initial differentiation phases directing pluripotent stem cells toward retinal fate [27]. Inhibition of BMP signaling in other model systems severely impairs regenerative responses, highlighting its fundamental role in cell fate determination [25] [26].

SHH signaling, activated through Smoothened agonists like SAG, promotes retinal cell specification and organizational maturation. The pathway functions through a well-defined cascade involving Patched receptors, Smoothened transduction, and Gli transcription factors that activate genes involved in neural repair and patterning [28] [29].

Retinoic Acid signaling exhibits precisely timed biphasic regulation critical for proper photoreceptor development. Early RA inhibition promotes cell cycle exit and increases cone genesis, while later inhibition alters cone subtype specification [30]. The RA-catabolizing enzyme CYP26A1 shows biphasic expression in the forming human macula, creating temporal windows of RA signaling that differentially influence developmental processes [30].

Optimized Protocols for Retinal Organoid Differentiation

Accelerated 90-Day Protocol

This protocol achieves mature retinal organoids in approximately two-thirds the time required by conventional methods through optimized pharmacological modulation [27] [31].

Table 2: Accelerated 90-Day Retinal Organoid Differentiation Protocol

Stage	Timing	Key Components	Purpose	Expected Outcomes
Neural Retinal Induction	DD0-DD10	Dual SMAD inhibition (SB431542, LDN193189) + BMP4 (DD1-DD3) [27]	Direct PSCs toward neuroectoderm and retinal fate	Formation of tightly packed neural retinal progenitor clusters
Retinal Cell Specification	DD10-DD40	SAG (100 nM) + Activin A (100 ng/mL) + all-trans RA (1 μM) [27]	Promote rapid retinal cell specification and initial differentiation	Emergence of retinal cell types; organization of neural retinal layers
Retinal Maturation	DD40-DD90	SAG alone [27]	Support robust lamination and photoreceptor maturation	Well-organized outer layers; hair-like surface structures; expression of rhodopsin and L/M opsin [27]

Figure 2: Accelerated 90-Day Retinal Organoid Differentiation Workflow. The optimized protocol employs sequential pharmacological treatments: initial BMP4 for retinal induction, combination SAG/Activin A/RA for specification, and SAG alone for maturation, achieving stage 3 organoids by day 90.

Enhanced Maturation Protocol (140 Days)

For applications requiring advanced structural features, this extended protocol generates photoreceptors with budding calyceal process-like structures and Usher protein expression within 140 days [18].

Key modifications from day 90 onward:

• Culture Medium: Switch to Advanced DMEM/F-12 with GlutaMAX supplement [18]
• Supplements: Continue SAG and B27 supplement without retinoic acid [18]
• Structural Outcomes: Photoreceptors display compartmentalized architecture with distinct inner/outer segments, connecting cilia, and emerging calyceal process-like structures [18]

Quantitative Outcomes Comparison

Table 3: Performance Metrics of Optimized Protocols

Parameter	Conventional Methods	Accelerated Protocol (90-Day)	Enhanced Protocol (140-Day)
Time to Maturity	120-170 days [27]	90 days [27]	140 days [18]
Differentiation Rate	Variable	~85% (based on structural characteristics) [27]	High efficiency [18]
Key Structural Features	Basic laminated structure	Hair-like surface structures; well-organized outer layers [27]	Budding calyceal processes; compartmentalized photoreceptor segments [18]
Photoreceptor Markers	Rhodopsin, Opsins	Rhodopsin, L/M Opsin [27]	Usher proteins; advanced outer segment proteins [18]
Applications	Basic research, disease modeling	Drug screening, medium-throughput studies [27]	Disease modeling of ciliopathies, advanced structural studies [18]

The Scientist's Toolkit: Essential Research Reagents

Table 4: Critical Reagents for Retinal Organoid Differentiation

Reagent	Function	Working Concentration	Key References
BMP4	Induces neural retinal fate from PSCs	3 nM (DD1-DD3) [27]	[27]
SAG (Smoothened Agonist)	Activates SHH signaling; promotes cell specification and maturation	100 nM (DD10 onward) [27]	[27] [28]
Activin A	Supports retinal cell specification	100 ng/mL (DD10-DD40) [27]	[27]
All-trans Retinoic Acid	Drives photoreceptor maturation	1 μM (DD10-DD40) [27]	[27] [30]
SB431542	TGF-β/Activin inhibitor; dual SMAD inhibition	10 μM [27]	[27]
LDN193189	BMP receptor inhibitor; dual SMAD inhibition	100 nM [27]	[27]
Taurine	Supports photoreceptor development and survival	100 μM [27]	[27] [18]

Technical Notes and Troubleshooting

Critical Timing Considerations

The timing of Retinoic Acid exposure is particularly crucial, as biphasic suppression via CYP26A1 naturally occurs during human macular development [30]. Early RA inhibition (mimicking the first CYP26A1 wave) prompts cell cycle exit and increases cone genesis, while late inhibition (mimicking the second wave) alters cone subtype specification [30]. Disruption of this precise temporal sequence can result in improper photoreceptor ratios or impaired maturation.

Quality Assessment Metrics

• Morphological Indicators: Stage 3 organoids exhibit hair-like surface structures representing primitive inner/outer segments and a clearly organized outer layer [27] [18]
• Molecular Markers: Spatial immunostaining for rhodopsin (rod photoreceptors), L/M opsin (cone photoreceptors), and CRX (photoreceptor nuclei) confirms proper differentiation [27]
• Structural Validation: Advanced maturation includes budding calyceal process-like structures and compartmentalized photoreceptor architecture [18]

Protocol Adaptation Tips

For disease modeling applications requiring specific photoreceptor subtypes, consider modifying RA timing based on target cells: earlier exposure favors cone genesis, while later manipulation influences subtype specification [30]. For enhanced structural maturation, extend culture duration to 140 days with antioxidant and lipid supplementation [18].

The strategic modulation of BMP, SHH, Activin A, and Retinoic Acid signaling pathways enables highly reproducible and efficient generation of human retinal organoids with advanced structural maturity. The protocols detailed herein provide researchers with optimized frameworks for producing retinal organoids suitable for diverse applications ranging from medium-throughput drug screening to sophisticated disease modeling of retinal disorders, particularly those involving photoreceptor ciliary architecture such as Usher syndrome. The significant reduction in culture time—achieving mature organoids in 90 days—substantially enhances the practicality and accessibility of this technology for basic and translational research.

Retinal organoids (ROs) are three-dimensional (3D) structures derived from human pluripotent stem cells (hPSCs) that mimic the spatial and temporal differentiation of the human retina [32]. They have become an indispensable in vitro model for studying retinal development, disease mechanisms, and for screening potential therapeutics [3] [32]. The process of generating ROs recapitulates in vivo retinogenesis, resulting in self-organizing tissues containing a variety of retinal cell types, including photoreceptors (rods and cones), retinal ganglion cells, bipolar cells, horizontal cells, amacrine cells, and Müller glia [3] [32]. This protocol outlines a highly reproducible, stepwise differentiation method for generating mature retinal organoids, designed for researchers and drug development professionals working on highly reproducible retinal organoid differentiation methods.

Materials and Reagents

Research Reagent Solutions

The following table details the essential reagents and their functions in the retinal organoid differentiation process.

Table 1: Key Research Reagents and Their Functions in Retinal Organoid Differentiation

Reagent Category	Specific Examples	Function in Differentiation Protocol
Pluripotent Stem Cell Source	Human Embryonic Stem Cells (hESCs), Induced Pluripotent Stem Cells (hiPSCs)	Starting material for generating retinal organoids; preserves donor genetic background [3] [32].
Signaling Pathway Inhibitors	IWR1-ε (Wnt inhibitor), LDN193189 (BMP inhibitor), SB431542 (TGF-β inhibitor), DAPT (Notch inhibitor)	Directs cell fate toward retinal lineage by suppressing non-retinal signaling pathways [32] [33].
Growth Factors & Hormones	IGF1, bFGF, T3 (Triiodothyronine), Retinoic Acid	Promotes survival, proliferation, and maturation of retinal progenitor cells and photoreceptors [32] [33].
Extracellular Matrix (ECM) Components	Matrigel, Recombinant Laminin-521 (rLN-521)	Provides a scaffold for 3D cell growth and self-organization; critical for optic vesicle formation [33].
Serum & Supplements	Foetal Bovine Serum (FBS), Human Platelet Lysate (HPL), B-27 Supplement, N-2 Supplement	Provides essential nutrients and factors for cell growth and maturation; HPL enables xeno-free conditions [33].
Amino Acids & Nutrients	Taurine, Non-Essential Amino Acids (NEAA), GlutaMAX	Supports metabolic needs of developing neural tissue and promotes photoreceptor health [32] [33].

Protocol: Stepwise Differentiation of Retinal Organoids

The differentiation process is segmented into four distinct phases, summarized in the table below.

Table 2: Summary of Retinal Organoid Differentiation Phases and Key Outcomes

Differentiation Phase	Timeframe (Approx.)	Key Morphological Events	Critical Cell Markers Expressed
1. hPSC Aggregation & Neural Induction	Days 0 - 10	Formation of uniform embryoid bodies (EBs) or 3D aggregates.	PAX6, RAX (Eye field specification) [33].
2. Retinal Progenitor Specification & Optic Vesicle Formation	Days 10 - 30	Emergence and budding of optic vesicle (OV)-like structures.	VSX2 (Retinal progenitor cells) [33].
3. Retinal Layer Patterning & Neurogenesis	Weeks 4 - 20	Lamination into distinct nuclear and plexiform layers.	CRX, RECOVERIN (Photoreceptor precursors); PKCα (Bipolar cells) [33].
4. Photoreceptor Maturation	Weeks 20 - 36+	Elaboration of outer segment-like structures.	NRL (Rods), OPN1SW/S-opsin, OPN1MW/L-M opsin (Cones), RHO (Rhodopsin) [33].

Phase 1: hPSC Aggregation and Neural Induction

This initial phase aims to generate uniform 3D cell aggregates and guide them toward a neural and eye-field fate.

• Procedure:
  • hPSC Dissociation: Culture hPSCs to high confluence. Dissociate the cells into a single-cell suspension using a gentle cell dissociation reagent.
  • Aggregate Formation: Seed the dissociated cells into agarose micromoulds (AMM) or low-attachment U-bottom plates to promote the formation of uniform, self-assembled 3D aggregates (EBs). The AMM platform standardizes the generation of EBs, enhancing reproducibility and scale [33].
  • Neural Induction Medium: Culture the aggregates in a neural induction medium. From day 1, add small molecule inhibitors to direct differentiation:
    • IWR1-ε (Wnt pathway inhibitor) to initiate neural and eye field specification [33].
    • LDN193189 (BMP inhibitor) and SB431542 (TGF-β inhibitor) to further support neural induction [32].

Phase 2: Retinal Progenitor Specification and Optic Vesicle Formation

During this phase, the aggregates commit to a retinal fate and form OVs, the precursors to the retina.

• Procedure:
  • Medium Transition: Between days 10 and 14, transition the cultures to a retinal differentiation medium.
  • Signaling Pathway Modulation: Continue with specific small molecules to pattern the neural tissue into retinal progenitor cells (RPCs). The timing and combination of these molecules are critical for efficient OV formation [33].
  • OV Maturation: Maintain the cultures until OV structures become visibly apparent as budding, translucent structures, typically from day 20 onwards. In some protocols, these OVs are manually microdissected to isolate pure retinal tissue, but the use of AMMs can make this step unnecessary [33].

Phase 3: Retinal Layer Patterning and Neurogenesis

The OVs develop into laminated retinal organoids with emerging neuronal cell types.

• Procedure:
  • Suspension Culture: Transfer the isolated OVs or entire AMM cultures to low-attachment plates for long-term suspension culture.
  • Maturation Medium: Culture the organoids in a medium supplemented with FBS (or HPL for xeno-free conditions), taurine, and retinoic acid to promote neuronal differentiation and survival [33].
  • NOTCH Inhibition: Adding DAPT (a NOTCH pathway inhibitor) around this stage can promote neurogenesis by driving RPCs to exit the cell cycle and differentiate into neurons [32] [33].

Phase 4: Photoreceptor Maturation

The final and longest phase focuses on the functional maturation of photoreceptors.

• Procedure:
  • T3 and Retinoic Acid Supplementation: Add triiodothyronine (T3) and continue retinoic acid to specifically enhance photoreceptor maturation, including the formation of outer segment-like structures [32].
  • Long-Term Culture: Maintain the organoids for an extended period (up to 36 weeks or more), with regular medium changes. Over time, the organoids will show distinct lamination, with an outer nuclear layer (ONL) rich in photoreceptors expressing markers like RHO and RCVRN, and an inner nuclear layer (INL) with bipolar cells labeled by PKCα [33].
  • Functional Assessment: Maturity can be assessed via immunohistochemistry for phototransduction proteins (e.g., Rhodopsin), the presence of outer segment-like structures visualized by electron microscopy, and electrophysiological studies.

Figure 1: Retinal Organoid Differentiation Workflow. This diagram outlines the four major phases and key signaling molecules used to direct the differentiation of hPSCs into mature retinal organoids.

Critical Signaling Pathways and Their Regulation

The stepwise differentiation is governed by the precise manipulation of key signaling pathways. The following diagram and table summarize the core pathways targeted to guide retinal fate.

Figure 2: Key Signaling Pathways in Retinogenesis. This diagram shows the primary signaling pathways manipulated during differentiation and the outcomes of their regulation.

Table 3: Regulation of Key Signaling Pathways in Retinal Organoid Differentiation

Signaling Pathway	Role in Retinal Development	Pharmacological Modulator	Effect in Protocol
Wnt/β-catenin	Inhibits anterior neural fate; its suppression is required for eye field formation [32].	IWR1-ε (Inhibitor)	Directs cells toward anterior neuroectoderm and retinal progenitor fate [33].
BMP	Promotes non-neural, epidermal fate; inhibition is necessary for neural induction.	LDN193189 (Inhibitor)	Works synergistically with Wnt inhibition to specify neural lineage [32].
Notch	Maintains progenitor cells in a proliferative state; inhibition allows for differentiation.	DAPT (Inhibitor)	Promotes cell cycle exit and differentiation of RPCs into retinal neurons [32] [33].
Sonic Hedgehog (SHH)	Patterns the neural tube and promotes RPC proliferation.	Agonists (e.g., SAG)	Used in some protocols to support the growth and patterning of retinal tissue [33].

This application note provides a detailed, step-by-step protocol for the highly reproducible generation of retinal organoids from hPSCs. By leveraging a defined sequence of small molecules and growth factors within a standardized 3D aggregation system, researchers can reliably recapitulate key stages of human retinogenesis. The methodologies outlined here, including the option for xeno-free culture, provide a robust platform for advanced research in disease modeling, drug discovery, and the development of cell-based therapies for retinal degenerative diseases.

Retinal organoids, three-dimensional in vitro structures derived from human pluripotent stem cells (hPSCs), have emerged as powerful tools for studying human retinogenesis, disease modeling, and drug screening [11]. However, limitations in the efficiency and reproducibility of traditional differentiation protocols have hampered their broader application in high-throughput research settings [12]. Variability in organoid size and morphology significantly contributes to this inconsistency, leading to asynchronous differentiation and reduced experimental reliability.

Recent advancements have addressed these challenges through standardized methodologies that regulate organoid size and shape using quick reaggregation techniques [12]. These approaches yield retinal organoids with enhanced reproducibility compared to traditional methods, enabling more reliable outcomes for basic and translational research. This protocol details the implementation of these novel techniques to achieve highly reproducible retinal organoid differentiation, specifically focusing on size regulation via quick reaggregation and the timed activation of BMP signaling to direct retinal fate with 100% efficiency across multiple widely used cell lines [12].

Key Principles and Experimental Basis

Fundamental Concepts

The core innovation presented here combines physical manipulation of cell aggregates with precise biochemical signaling to override the inherent variability of spontaneous retinal differentiation. Regulation of organoid size and shape through quick reaggregation methods generates highly reproducible retinal organoids by ensuring consistent starting material and subsequent developmental cues [12]. This method directly addresses the limitations of traditional approaches where irregular embryoid body formation leads to heterogeneous differentiation outcomes.

Timed activation of bone morphogenetic protein (BMP) signaling within developing cells serves as a critical fate determinant, generating pure populations of retinal organoids at 100% efficiency from multiple widely used hPSC lines [12]. The research demonstrates that the default forebrain fate results specifically from the inhibition of BMP signaling, highlighting the pivotal role of this pathway in retinal specification. This targeted approach bypasses the inefficient multi-lineage differentiation that often occurs in conventional protocols.

Supporting Experimental Evidence

Studies implementing these techniques have demonstrated remarkable improvements in differentiation efficiency and reproducibility. The method yields retinal organoids with expedited differentiation timelines compared to traditional approaches, potentially reducing the culture period required for mature photoreceptor generation [12]. The ability to direct retinal or forebrain fates at complete purity has enabled researchers to identify some of the earliest transcriptional changes that occur during the specification of these two lineages from a common progenitor through mRNA-seq analyses [12].

Materials and Reagent Solutions

Research Reagent Solutions

Item	Function in Protocol
Laminin 511-E8 fragment	Culture plate coating for iPSC maintenance; promotes cell adhesion [18]
StemFit medium	Defined, xeno-free maintenance medium for human iPSCs [18]
Glasgow's Minimum Essential Medium (GMEM)	Base medium for initial differentiation [18]
KnockOut Serum Replacement (KSR)	Serum replacement used in early differentiation phase [18]
1-Monothioglycerol (MTG)	Antioxidant supplement replacing β-mercaptoethanol [18]
Bone Morphogenetic Protein 4 (BMP4)	Key signaling molecule directing retinal fate specification [12] [18]
DMEM/F-12 with GlutaMAX	Base medium for maturation stages [18]
N2 Supplement	Serum-free supplement for neural differentiation [18]
B27 Supplement (without retinoic acid)	Serum-free supplement for neuronal cell culture [18]
Fetal Bovine Serum (FBS)	Serum supplement for maturation media (can be replaced with human platelet lysate for xeno-free conditions) [18]
All-trans Retinoic Acid (RA)	Signaling molecule promoting photoreceptor differentiation [18]
Taurine	Amino acid that supports photoreceptor development and survival [18]
Smoothened Agonist (SAG)	Small molecule agonist of the Sonic hedgehog pathway [18]
Activin A	TGF-β family cytokine supporting retinal differentiation [18]
Recombinant Laminin 521 (rLN-521)	Xeno-free alternative to Matrigel for substrate coating [33]
Human Platelet Lysate (HPL)	Xeno-free alternative to FBS [33]

Methodologies

Size Regulation and Quick Reaggregation Protocol

hPSC Maintenance and Preparation

• Maintain human iPSCs in StemFit medium on culture plates coated with laminin 511-E8 fragment [18].
• For differentiation preparation, seed cells in a 6-well plate at a density of 5,000 cells/well and culture for 10 days in StemFit medium until cells form dense colonies [18].
• Ensure iPSCs are in a pluripotent state with typical morphology before initiation of differentiation.

Formation of Standardized Aggregates

• Dissociate iPSC colonies into single cells using appropriate dissociation reagent.
• Utilize agarose micromould (AMM) platform to generate uniform self-assembled 3D spheres from dissociated hPSCs [33].
• Seed cell suspension into AMM containing microwells of 800 μm in diameter and depth [33].
• Scale up production by culturing multiple AMMs in multi-well plates (e.g., 972 microwells per 12-well plate) [33].
• Culture until aggregates form tightly packed, uniform structures ready for retinal induction.

Retinal Differentiation via Quick Reaggregation

• Replace culture medium with differentiation medium consisting of GMEM supplemented with 10% KSR, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 450 μM MTG from differentiation day (DD)0 to DD10 [18].
• Add BMP4 (3 nM) from DD1 to DD3 to direct cells toward retinal fate [12] [18].
• On DD10, transfer tightly packed retinal clusters that have formed at the bottom of the culture dish to floating culture in Maturation Medium 1 (DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, and 100 μM taurine) [18].
• From DD10 to DD40, add 100 nM SAG, 100 ng/mL activin A, and 1 μM all-trans retinoic acid to Maturation Medium 1 [18].
• From DD40 to DD90, continue culture with SAG and B27 supplement without retinoic acid added to Maturation Medium 1 [18].

Signaling Pathway Activation

Figure 1: Retinal Organoid Differentiation Workflow. This diagram illustrates the key stages from hPSC preparation to mature retinal organoid formation, highlighting the critical BMP4 treatment window.

Advanced Maturation and Characterization

• From DD90 onward, switch culture medium to Maturation Medium 2 (Advanced DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, and 100 μM taurine) [18].
• Continue supplementation with SAG and B27 supplement without retinoic acid for the remainder of the culture period.
• Monitor organoid development phase contrast microscopy, with typical retinal organoids exhibiting distinct morphological features including pigmented regions and neural rosette structures.
• Assess retinal specification and maturation through immunohistochemical analysis of key markers including PAX6, CRX, RECOVERIN, and photoreceptor-specific opsins [18].
• Evaluate structural maturation through electron microscopy to identify advanced features such as inner/outer segment formation and calyceal process-like structures [18].

Results and Data Presentation

Quantitative Outcomes of Enhanced Protocol

Table 1: Efficiency Metrics of Size-Regulated Retinal Organoid Differentiation

Parameter	Traditional Methods	Size Regulation & Quick Reaggregation
Differentiation Efficiency	Variable, line-dependent	100% efficiency across multiple cell lines [12]
Protocol Duration	Extended timelines (~180 days for structural maturation)	Expedited differentiation (~140 days for advanced features) [12] [18]
Organoid Uniformity	High variability in size and morphology	Highly reproducible size and shape [12]
Photoreceptor Maturation	Limited structural complexity in standard timeframes	Budding calyceal process-like structures observed [18]
Transcriptional Analysis	Difficult due to mixed populations	Enabled identification of earliest lineage specification events [12]

Structural and Molecular Characterization

Table 2: Temporal Progression of Retinal Organoid Development and Marker Expression

Differentiation Stage	Time Period	Key Morphological Features	Molecular Markers
Retinal Specification	DD1-DD10	Formation of uniform aggregates, neuroepithelium emergence	PAX6, RAX [18]
Early Morphogenesis	DD10-DD40	Optic vesicle-like structures, neural retina patterning	VSX2, CRX [18]
Photoreceptor Genesis	DD40-DD90	Stratified architecture, outer nuclear layer formation	CRX, RECOVERIN, NRL [18]
Advanced Maturation	DD90-DD140	Inner/outer segment formation, synaptic connectivity	RHO, OPSIN, PKCα, Synaptophysin [18]
Structural Specialization	DD140+	Budding calyceal process-like structures, outer segment disks	Usher proteins, PRPH2, GNAT1 [18]

Discussion

Technical Advantages and Implementation Considerations

The combination of size regulation through quick reaggregation and timed BMP activation represents a significant advancement in retinal organoid technology. The physical standardization of organoid size addresses a critical source of variability, while the precise biochemical manipulation of BMP signaling eliminates the stochastic elements of spontaneous retinal differentiation [12]. This synergistic approach enables the generation of highly reproducible retinal organoids suitable for analyzing the earliest stages of human retinal cell fate specification [12].

Researchers should note that the 100% efficiency in retinal fate specification represents a dramatic improvement over traditional methods, potentially eliminating the need for manual selection of retinal structures [12]. The emergence of budding calyceal process-like structures within 140 days indicates enhanced structural maturation under these optimized conditions [18]. These advanced features are particularly valuable for disease modeling of ciliary disorders such as Usher syndrome, where periciliary architecture is disrupted [18].

Application in Research and Drug Development

For researchers and drug development professionals, these techniques enable more standardized and reproducible experimental systems. The ability to generate pure populations of retinal organoids at scale supports high-throughput screening applications that were previously challenging with variable differentiation outcomes [12]. The expedited differentiation timeline also reduces resource requirements for long-term culture maintenance while still achieving advanced maturation features [12] [18].

The reproducibility of this method across multiple cell lines enhances its utility for disease modeling, particularly when working with patient-derived iPSCs where consistent differentiation is essential for meaningful phenotypic comparisons [12]. The defined, serum-free adaptations of this protocol further support its application in translational research and potential clinical applications [33].

Retinal organoids, three-dimensional tissues derived from pluripotent stem cells (PSCs), have emerged as indispensable tools for modeling retinal diseases, drug screening, and developing regenerative therapies [27] [1]. A significant limitation in their application has been the extended time required for maturation—typically 120 to 170 days—which constrains research throughput [27] [34]. Recent advances in protocol optimization now enable the generation of mature retinal organoids with advanced features, including well-laminated structures, inner/outer segment-like formations, and functional photoreceptors, within a significantly reduced timeframe of 90 to 140 days [27] [12]. This Application Note details these accelerated maturation protocols, providing structured methodologies and analytical tools to support highly reproducible retinal organoid research.

The table below summarizes key performance metrics from recent studies demonstrating accelerated retinal organoid maturation.

Table 1: Quantitative Metrics of Accelerated Retinal Organoid Protocols

Study Reference	Maturation Timeframe	Key Efficiency Metrics	Advanced Features Demonstrated
PMC11315325 [27]	90 days	100% efficiency in generating pure retinal organoid populations from multiple cell lines; maturation in ~2/3 the time of conventional methods.	Hair-like surface structures (inner/outer segments); well-organized outer layers; expression of rhodopsin and L/M opsin; reduced ectopic cone generation.
Proc Natl Acad Sci U S A [12]	Expedited timeline (specific days not stated)	100% efficiency from multiple widely used cell lines; highly reproducible with minimal variability.	Expedited differentiation; suitable for high-throughput applications.
J Transl Genet Genom [35]	85-200 days (accelerated features by day 85)	Method 3 yielded 65 ± 27 retinal domains per differentiation, significantly more than other methods.	Significant CRX-positive photoreceptors and BRN3A-positive ganglion cells at day 85; mature rod and cone markers at day 200.

Detailed Experimental Protocol for 90-Day Maturation

This protocol, adapted from a 2024 study, utilizes precise pharmacological interventions to accelerate retinal organoid development [27].

Initial Neural Retinal Induction (Days 0-10)

• Objective: Direct human induced PSCs (iPSCs) toward neural retinal progenitor fate.
• Key Reagent Solutions:
  • Small Molecules: Dual SMAD inhibition using SB431542 (10 μM) and LDN193189 hydrochloride (100 nM).
  • Growth Factor: BMP4 (3 nM).
• Methodology:
  • Culture human iPSCs in StemFit medium on laminin 511-E8 coated plates until they form tightly packed colonies (approximately 10 days after seeding at 5,000 cells/well) [27].
  • On differentiation day (DD) 0, switch to a differentiation medium containing Glasgow's Minimum Essential Medium supplemented with 10% KnockOut Serum Replacement, non-essential amino acids, sodium pyruvate, penicillin, streptomycin, and 1-monothioglycerol [27].
  • At DD0 and DD1, add the SMAD signaling inhibitors SB431542 and LDN193189 to the culture medium.
  • From DD1 to DD3, replace the medium with one containing only BMP4 (3 nM) to promote neuroectoderm and retinal fate [27].
  • From DD3 to DD10, continue culture in the base differentiation medium without additional inductive factors.

Accelerated Retinal Specification (Days 10-40)

• Objective: Rapidly specify retinal cell types.
• Key Reagent Solutions:
  • Signaling Agonists: Sonic hedgehog agonist (SAG, 100 nM).
  • Growth Factors & Hormones: Activin A (100 ng/mL) and all-trans retinoic acid (1 μM).
• Methodology:
  • At DD10, gently lift the tightly packed clusters of neural retinal progenitors and transfer to a floating culture in a maturation medium. The base maturation medium consists of DMEM/F-12 with GlutaMAX, 10% fetal bovine serum, N2 supplement, and 100 μM taurine [27].
  • From DD10 to DD40, supplement the maturation medium with a combination of SAG (100 nM), activin A (100 ng/mL), and all-trans retinoic acid (1 μM) [27].
  • Change the medium every other day.

Robust Retinal Maturation (Days 40-90)

• Objective: Promote robust laminar organization and photoreceptor maturation.
• Key Reagent Solutions:
  • Signaling Agonist: SAG (100 nM) alone.
• Methodology:
  • At DD40, switch the supplementation to SAG (100 nM) alone, which is continuously present in the maturation medium throughout the rest of the culture period [27].
  • Continue the floating culture with medium changes every other day until DD90.
  • By DD90, the organoids should display defined outer lamina with budding hair-like structures, indicative of advanced maturation [27].

Signaling Pathway and Workflow Visualization

The accelerated protocol leverages precise temporal control of key developmental signaling pathways. The following diagram illustrates the sequential pharmacological activation that drives rapid and efficient retinogenesis.

Diagram Title: Temporal Control of Signaling Pathways in Accelerated Retinogenesis

The experimental workflow from pluripotent stem cells to mature retinal organoids is outlined below.

Diagram Title: Workflow for 90-Day Retinal Organoid Differentiation

The Scientist's Toolkit: Research Reagent Solutions

Critical reagents and their functional roles in the accelerated maturation protocol are detailed in the following table.

Table 2: Essential Research Reagents for Accelerated Retinal Organoid Differentiation

Reagent	Functional Role in Protocol	Key Application Details
SMAD Inhibitors (SB431542, LDN193189)	Directs pluripotent stem cells toward neuroectodermal lineage by inhibiting TGF-β/Activin and BMP signaling pathways.	Used at initiation of differentiation (DD0-DD1) [27].
Bone Morphogenetic Protein 4 (BMP4)	Promoves retinal pigment epithelium (RPE) and neural retinal fate after initial neural induction.	Critical early signal (DD1-DD3); concentration at 1.5-3 nM [27] [35].
Sonic Hedgehog Agonist (SAG)	Activates SHH signaling, enhancing survival of neural cells and promoting photoreceptor differentiation.	Used continuously from DD10 onwards at 100 nM [27].
Activin A	A TGF-β family member that supports retinal specification and patterning.	Applied during the specification phase (DD10-DD40) at 100 ng/mL [27].
all-trans Retinoic Acid (RA)	A potent morphogen that promotes photoreceptor differentiation and maturation.	Used during the specification phase (DD10-DD40) at 1 μM [27].

Quality Assessment & Validation Methods

Rigorous validation is essential to confirm that accelerated organoids recapitulate features of native retina.

• Morphological Assessment: Use bright-field microscopy to identify stage 3 organoids, characterized by hair-like surface structures representing inner/outer segment formation and a clearly organized outer layer [27] [34].
• Immunohistochemical Analysis: Validate cellular composition and laminar organization using antibodies against key markers. In mature organoids, expect rhodopsin (rod photoreceptors) and L/M opsin (cone photoreceptors) localized to the outermost layer; CRX (photoreceptor precursors); and markers for bipolar cells, amacrine cells, and ganglion cells in appropriate laminar positions [27] [14] [35].
• Advanced Phenotyping: Employ multimodal spatiotemporal phenotyping, such as multiplexed immunofluorescence imaging, to quantify progenitor and neuron location, extracellular matrix arrangements, and global patterning at single-cell resolution [36]. Single-cell RNA sequencing can validate that organoid cell transcriptomes converge toward those of adult human retinal cell types [14].

The protocols detailed herein demonstrate that accelerated maturation of human retinal organoids to a advanced stage within 90 days is achievable through optimized, timed pharmacological interventions. Key to this success is the sequential application of SMAD inhibition, BMP4, and the combination of SAG, activin A, and retinoic acid, followed by SAG alone. This significant reduction in culture time, coupled with high efficiency and reproducibility, positions these protocols as powerful tools for accelerating research in retinal disease modeling, high-throughput drug discovery, and the development of transplantation therapies.

Retinal organoids, three-dimensional multicellular structures derived from human pluripotent stem cells (hPSCs), have emerged as a transformative in vitro model system that closely mirrors the spatial and temporal patterning of the developing human retina [37]. These structures contain all major retinal cell types—including rod and cone photoreceptors, bipolar cells, horizontal cells, amacrine cells, retinal ganglion cells (RGCs), and Müller glia—organized into layered architectures reminiscent of native retinal tissue [38] [36]. The integration of retinal organoid technology into biomedical research has created unprecedented opportunities for understanding retinal development, disease mechanisms, and therapeutic interventions. This application note details standardized protocols and analytical frameworks for implementing retinal organoids in disease modeling, drug screening, and regenerative medicine, with emphasis on methodology reproducibility and quantitative assessment.

The human retina comprises over 100 distinct cell types arranged in a complex laminated structure that is susceptible to a spectrum of degenerative conditions [39]. Inherited retinal diseases (IRDs) alone involve more than 270 causative genes, while age-related conditions like macular degeneration and glaucoma represent leading causes of irreversible blindness worldwide [38] [37]. Traditional animal models, while valuable, exhibit significant limitations due to species-specific differences in retinal anatomy, photoreceptor types, and genomic conservation [38]. Retinal organoids address these limitations by providing a human-derived system that recapitulates key aspects of retinal development and disease pathology, enabling researchers to study disease mechanisms in a human genetic context and accelerating the development of personalized therapies [38] [36].

High-Reproducibility Differentiation Methods

Recent methodological advances have substantially improved the efficiency, reproducibility, and scalability of retinal organoid generation. Key innovations include standardized aggregation techniques, optimized signaling pathway modulation, and culture system enhancements that collectively address previous limitations in protocol variability and yield.

Scalable Production Workflows

Dr. Magdalena Renner's lab pioneered high-throughput retinal organoid production through two critical innovations: controlled embryoid body (EB) formation using agarose microwell arrays and "checkerboard scraping" for efficient organoid harvesting [39]. This approach enables generation of thousands of retinal organoids per well, a significant improvement over traditional methods yielding only three organoids per well. The standardized EB formation proved particularly pivotal, as embryoid body size critically influences organoid differentiation outcomes [39]. This method replacement of labor-intensive manual microdissection with checkerboard scraping allows researchers to harvest hundreds of developmentally synchronized organoids in a fraction of the time previously required.

Harkin et al. developed a highly reproducible differentiation method achieving 100% efficiency across multiple widely used hPSC lines through regulation of organoid size and shape using quick reaggregation methods [12]. This protocol employs timed activation of BMP signaling to generate pure retinal organoid populations, with the default forebrain fate resulting from BMP inhibition [12]. The methodology yields retinal organoids with expedited differentiation timelines compared to traditional approaches, making it particularly suitable for high-throughput applications [12].

Advanced Maturation Protocols

An optimized differentiation protocol developed by Tokyo University of Science researchers generates retinal organoids exhibiting advanced photoreceptor maturation within 140 days—significantly shorter than the 180+ days typically required [18]. This protocol produces photoreceptors with compartmentalized architecture, including distinct inner and outer segments, connecting cilia, and budding calyceal process-like structures [18]. These features are particularly relevant for disease modeling, as disruption of ciliary and periciliary architecture is implicated in various inherited retinal dystrophies, including Leber's congenital amaurosis and retinitis pigmentosa [18].

Table 1: Comparison of Retinal Organoid Differentiation Methods

Method Feature	Traditional Approach	High-Throughput Method (Renner)	Highly Efficient Method (Harkin et al.)	Advanced Maturation Protocol
Initial EB Formation	Spontaneous aggregation	Agarose microwell arrays	Quick reaggregation	Modified laminin-based culture
Key Signaling Modulators	Basal media only	Not specified	Timed BMP activation	BMP4 + antioxidant/lipid supplementation
Efficiency	Variable	Thousands per well	100% across cell lines	Enhanced maturation
Time to Maturation	180-260 days [38]	~98 weeks with maintained structure [39]	Expedited timeline	140 days
Unique Features	Basic layered structure	HistoBrick compatible	Pure retinal populations	Calyceal process-like structures
Best Application	Basic development studies	Large-scale screening	Disease modeling	Photoreceptor pathology studies

Quantitative Analytical Frameworks

Comprehensive characterization of retinal organoids requires multimodal assessment across molecular, cellular, and structural domains. Advanced analytical techniques now enable detailed evaluation of organoid development and maturation.

Developmental Staging and Maturation Markers

Retinal organoid development progresses through three defined stages [38]. During Stage 1 (differentiation days 30-50), organoids develop a clear phase-bright outer neuroepithelial rim containing neural retina progenitors, with retinal ganglion cells (RGCs) appearing as the first differentiated cell type around day 50 [38]. Stage 2 (days 80-120) features development of a phase-dark core with reduced bright rim and emergence of early cone and rod progenitors [38]. Stage 3 (days 120-180) reveals a visible outer rim with hair-like brush-border structures corresponding to photoreceptor inner and outer segments [38]. The advanced maturation protocol demonstrates features beyond classic Stage 3, including compartmentalized inner/outer segments and budding calyceal process-like structures within 140 days [18].

Table 2: Retinal Organoid Maturation Markers and Assessment Timeline

Time Period	Structural Features	Key Molecular Markers	Functional Assessment	Model Applications
Days 30-50 (Stage 1)	Phase-bright rim, RGC formation	PAX6, VSX2	Immunohistochemistry	Early development, RGC disorders
Days 80-120 (Stage 2)	Phase-dark core, reduced rim	CRX, NRL	scRNA-seq, Immunostaining	Cell fate specification
Days 120-180 (Stage 3)	Brush-border structures (primitive IS/OS)	Recoverin, Rhodopsin, Opsins	4i, Electrophysiology	Photoreceptor development, IRDs
Days 180+ (Advanced Maturation)	Distinct IS/OS, connecting cilium, calyceal processes	Usher proteins, OS-specific proteins	TEM, Functional imaging	Usher syndrome, ciliopathies

Multimodal Phenotyping Technologies

A multimodal spatiotemporal phenotyping approach has been developed to quantitatively characterize retinal organoid development [36]. This method utilizes iterative indirect immunofluorescence imaging (4i) on histological sections, generating multiplexed protein maps with 53 antibody stains across retinal organoid time courses [36]. The computational pipeline includes unsupervised machine learning-based clustering of pixels (multiplexed tissue units or MTUs), nuclei segmentation, and analysis of nuclei heterogeneity and spatial arrangement from protein intensities [36]. This approach enables comprehensive characterization of tissue organization and composition in an unbiased manner, robust to the morphological heterogeneity observed within and between organoids [36].

The Laminator computational method reconstructs organoid laminar structure dynamics by establishing contours around organoids, segmenting adjacent laminar windows, quantifying signals across these windows, and applying graph embedding for trajectory reconstruction [36]. This analytical framework enables researchers to quantitatively track the emergence of retinal lamination—a critical feature for functional maturation—and compare patterning across experimental conditions or protocols.

Disease Modeling Applications

Inherited Retinal Diseases

Retinal organoids provide a physiologically relevant human model for investigating inherited retinal diseases (IRDs), which comprise a genetically and clinically heterogeneous subgroup of vision disorders [38]. By using induced pluripotent stem cells (iPSCs) derived from patients with specific genetic mutations, researchers can generate retinal organoids that recapitulate disease-specific pathophysiological processes at both cellular and molecular levels [38]. This approach is particularly valuable for studying photoreceptor-based IRDs, as the organoid photoreceptors express disease genes in the same cell types as the human retina, enabling investigation of disease mechanisms and screening of therapeutic interventions [39] [38].

Age-Related Macular Degeneration and Glaucoma

Retinal organoids also facilitate modeling of complex retinal conditions such as age-related macular degeneration (AMD) and glaucoma. AMD involves degeneration of retinal photoreceptors, retinal pigment epithelium (RPE), and Bruch's membrane, with current treatments for the wet form focusing on anti-VEGF therapies but no effective treatments available for the dry form [37]. Retinal organoids enable study of AMD pathogenesis and screening of potential RPE replacement strategies [37]. For glaucoma, characterized by progressive loss of RGCs and their axons, retinal organoids provide a system for investigating RGC development and survival [37]. Recent advancements include injections of RGCs derived from retinal organoids into mice with optic neuropathy, showing improved visual function and survival up to one month, highlighting potential translational applications [37].

Drug Screening Platforms

Retinal organoids have emerged as powerful platforms for drug discovery and therapeutic screening, enabling identification of neuroprotective compounds and efficacy testing of candidate therapies in a human-relevant system.

High-Throughput Compound Screening

The implementation of high-throughput retinal organoid production has enabled large-scale compound screening campaigns [39]. In a collaboration between Dr. Renner's lab and Novartis' FAST lab, researchers screened a 2,700-compound library for agents that protect cone photoreceptors from degeneration induced by metabolic stress [39]. The experimental system utilized viral vectors to express green fluorescent protein under a cone-specific promoter, enabling live imaging and quantification of cone survival over time [39]. Under low glucose conditions, approximately 40% of cone photoreceptors were lost within one week, providing a robust assay window for identifying protective compounds [39].

This screening approach identified two kinase inhibitors—designated "cone-saving kinase inhibitors 1 and 2"—that significantly increased cone survival at both 7 and 14 days [39]. Follow-up kinase profiling suggested casein kinase 1 and MAP kinase 11 as likely targets, respectively, highlighting potential pathways for targeted neuroprotective therapies [39]. This work demonstrates the feasibility of using retinal organoids for moderate-throughput screening campaigns to identify compounds with therapeutic potential for retinal degenerative diseases.

Protocol for High-Content Screening of Neuroprotective Compounds

Experimental Workflow:

• Generate retinal organoids using high-throughput method (agarose microwells or quick reaggregation)
• At day 120-140, transduce with cone-specific fluorescent reporter (e.g., GFP under cone arrestin promoter)
• Plate organoids in 96-well screening plates (1 organoid/well)
• Induce metabolic stress by switching to low glucose medium
• Add compound library (include positive and negative controls)
• Monitor cone survival via live imaging over 7-14 days
• Quantify fluorescence intensity and normalize to controls
• Confirm hits in secondary assays (histology, functional measures)

Key Parameters:

• Assay window: ~40% cone death in negative controls
• Z-factor: >0.4 for robust screening
• Endpoints: Cone survival at 7 and 14 days, morphological preservation
• Secondary validation: Immunostaining for photoreceptor markers, TUNEL apoptosis assay, electrophysiological function

Regenerative Medicine and Tissue Engineering

Retinal organoids represent a promising cell source for regenerative therapies aimed at restoring visual function in degenerative retinal conditions. Several approaches are being developed to translate organoid technology into clinical applications.

Cell Replacement Strategies

Photoreceptor precursor cells derived from retinal organoids show potential for transplantation therapies to replace lost photoreceptors in conditions such as retinitis pigmentosa and AMD [38] [37]. Studies have demonstrated that organoid-derived photoreceptors can integrate into host retinas and form synaptic connections, although efficiency remains a challenge [38]. For glaucoma, RGCs derived from retinal organoids have been injected into mice with optic neuropathy, showing improved visual function and survival for up to one month, highlighting potential for RGC replacement strategies [37].

Retinal pigment epithelium (RPE) replacement represents another promising application, particularly for AMD [37]. Since RPE dysfunction plays a central role in both dry and wet AMD pathogenesis, transplanting stem cell-derived RPE monolayers or bioengineered constructs holds potential for disease stabilization and vision restoration [37]. Retinal organoids frequently contain RPE cells that can be isolated and expanded for such applications.

Bioengineering and Transplantation Workflows

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful implementation of retinal organoid technology requires specific reagents, materials, and specialized tools. The following table details essential components for establishing reproducible retinal organoid differentiation and analysis pipelines.

Table 3: Essential Research Reagents and Materials for Retinal Organoid Research

Category	Specific Reagents/Materials	Function/Application	Protocol Examples
Stem Cell Culture	Human iPSCs/ESCs, Laminin-511/E8, mTeSR1/StemFit	Pluripotent cell maintenance and expansion	Maintenance culture on laminin-coated plates [18]
Differentiation Media	GMEM, DMEM/F12, KnockOut Serum Replacement (KSR), N2 Supplement, B27 Supplement	Support retinal fate specification and differentiation	GMEM + 10% KSR for initial differentiation [18] [38]
Signaling Modulators	BMP4, Noggin, Dkk-1, SAG (Smoothened Agonist), all-trans Retinoic Acid, DAPT	Direct retinal patterning and photoreceptor differentiation	BMP4 (DD1-3) for retinal fate [12] [18]; SAG for photoreceptor generation [18]
Maturation Enhancers	Taurine, 1-monothioglycerol, Lipid supplements, Antioxidants	Promote photoreceptor maturation and survival	Taurine (100μM) in maturation media [18] [38]
Analytical Tools	Antibody panels (63-plex for 4i), scRNA-seq reagents, HistoBrick molds	Multimodal phenotyping and high-throughput histology	4i with 53 antibodies for spatial protein mapping [36]; HistoBrick for parallel sectioning [39]
Specialized Equipment	Agarose microwell arrays, Confocal imaging systems, Single-cell sequencers	High-throughput production and advanced characterization	Agarose microwells for standardized EB formation [39]; Confocal microscopy for structural analysis [18]

Retinal organoid technology has established itself as an indispensable platform for studying human retinal development, disease mechanisms, and therapeutic interventions. The continued refinement of differentiation protocols—emphasizing reproducibility, efficiency, and advanced maturation—will further enhance the utility of these systems for both basic research and translational applications. Future developments will likely focus on improving organoid vascularization, enabling better nutrient delivery and prolonged survival; enhancing functional maturation through co-culture systems or bioengineering approaches; and developing standardized validation frameworks to ensure consistency across laboratories and applications.

The integration of retinal organoids with emerging technologies such as high-content spatial omics, functional imaging, and bioengineering approaches will create increasingly sophisticated models of retinal development and disease. These advances promise to accelerate the development of novel therapies for currently untreatable retinal conditions, ultimately contributing to the preservation and restoration of vision for patients worldwide. As the field progresses, the implementation of highly reproducible differentiation methods and standardized analytical frameworks will be crucial for generating robust, comparable data across studies and translating retinal organoid technology into clinical applications.

Troubleshooting Common Challenges and Protocol Optimization Strategies

Addressing Line-to-Line Variability and Batch Effects

The adoption of human pluripotent stem cell (hPSC)-derived retinal organoids in biomedical research represents a paradigm shift in modeling retinal development and disease. However, their full potential in drug discovery and regenerative medicine is hampered by significant challenges related to line-to-line variability and batch effects. These inconsistencies can stem from intrinsic genetic differences in cell lines and extrinsic technical variations in differentiation protocols, threatening the reproducibility and reliability of experimental data. This application note details a standardized framework of protocols and quality control measures designed to systematically mitigate these sources of variability, thereby enhancing the rigor of retinal organoid-based research.

Data aggregated from recent studies highlight key phenotypic and transcriptional differences, underscoring the need to account for inherent biological variability when designing experiments.

Table 1: Summary of Hallmark Phenotypes in Familial AD vs. Control Retinal Organoids

Analyte / Measure	AD Retinal Organoids	Unaffected Control Organoids	Assay Method	Citation
Aβ42:Aβ40 Ratio	Significantly increased	Baseline	ELISA	[40]
Phosphorylated Tau (pTau) Protein	Significantly increased	Baseline	Immunocytochemistry, Western Blot	[40]
pTau Localization (Co-localization with MAP2)	Largest increase in inner regions (RGCs)	Lower, baseline expression	Immunofluorescence & Quantification	[40]
Differentially Expressed Genes (DEGs)	130 upregulated, 64 downregulated	Baseline transcriptional profile	Nanostring Transcriptional Profiling	[40]

Table 2: Protocol Efficiency and Maturation Timeline Comparison

Protocol Feature	Classic Protocol (Nakano et al.)	Improved Short-term Protocol	Advanced Maturation Protocol	Citation
Time to Stage 3 Retinal Organoids	~180 days or more	~90 days	~140 days	[18]
Key Structural Features	Basic laminated structure, primitive inner/outer segments	Well-defined ONL/OPL, hair-like protrusions	Compartmentalized inner/outer segments, connecting cilium, budding calyceal processes	[18]
Photoreceptor Maturation	Expression of opsins (e.g., RHO, OPSIN)	Robust outer segment protein expression	Usher protein expression in periciliary region	[18]

Experimental Protocols for Reproducible Retinal Organoid Differentiation

Standardized Retinal Organoid Differentiation Workflow

The following protocol, adapted from established methods, is designed to minimize batch-to-batch variation through precise timing and reagent control [18] [11].

Title: Retinal organoid differentiation workflow

Key Materials:

• Cell Line: Human iPSCs (e.g., 1231A3 line) [18].
• Basal Media: GMEM, DMEM/F-12, Advanced DMEM/F-12.
• Supplements: KnockOut Serum Replacement (KSR), N2 Supplement, B-27 Supplement without Vitamin A.
• Small Molecules: 1-Monothioglycerol (1-MTG), Smoothened Agonist (SAG), All-Trans Retinoic Acid (RA).
• Growth Factors: Bone Morphogenetic Protein 4 (BMP4), Activin A.

Detailed Procedure:

• Maintenance: Culture human iPSCs in StemFit medium on plates coated with laminin 511-E8 fragment until dense colonies form [18].
• Differentiation Initiation (DD0): Replace maintenance medium with differentiation medium (GMEM supplemented with 10% KSR, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 450 μM 1-monothioglycerol).
• Neural Induction (DD1-DD3): Add 3 nM BMP4 to the differentiation medium to direct cells toward retinal fate.
• Retinal Cluster Formation (DD10): By this stage, tightly packed retinal clusters form. Gently scrape and transfer these clusters to a floating culture in Maturation Medium 1 (DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 μM taurine) supplemented with 100 nM SAG, 100 ng/mL activin A, and 1 μM RA.
• Medium Adjustment (DD40): From DD40 to DD90, continue culture in Maturation Medium 1 but replace activin A and RA with B-27 supplement without retinoic acid. SAG supplementation continues.
• Final Maturation (DD90 onwards): Switch the culture medium to Maturation Medium 2 (Advanced DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 μM taurine) supplemented with SAG and B-27 without retinoic acid for the remainder of the culture period. Organoids can be harvested from DD140 for analysis [18].

Protocol for Assessing AD-Related Phenotypes in Retinal Organoids

This protocol outlines the methods for validating key disease phenotypes, which is critical for ensuring consistent modeling across different cell lines and batches [40].

Title: Retinal organoid AD phenotype analysis

Key Materials:

• Antibodies for Immunostaining: Anti-phospho-Tau (AT-8), anti-MAP2 (RGCs), anti-NRL (photoreceptors).
• Assay Kits: Human Aβ42 and Aβ40 ELISA Kits.
• Transcriptional Profiling: Nanostring Human Alzheimer's Disease Panel.

Detailed Procedure:

• Sample Preparation: Fix a subset of 5-month-old retinal organoids in 4% PFA for immunohistochemistry. For Western blot and ELISA, collect organoid lysates and conditioned culture media, respectively [40].
• Phosphorylated Tau (pTau) Analysis:
  • Perform immunostaining with AT-8 antibody on cryosections to visualize pTau localization. Co-staining with MAP2 and NRL identifies affected cell types. Quantify fluorescence intensity and the number of co-localized cells.
  • Validate findings via Western blot to calculate the pTau to total Tau ratio.
• Amyloid Beta Analysis: Use commercial ELISA kits to measure the concentrations of Aβ42 and Aβ40 peptides in conditioned media. Calculate the Aβ42:Aβ40 ratio, where a significant increase indicates AD pathology.
• Transcriptional Profiling: Isolve RNA from organoids and analyze using the Nanostring gene panel. Identify differentially expressed genes (DEGs) and perform pathway analysis to uncover altered biological processes.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Reproducible Retinal Organoid Research

Reagent / Material	Function / Purpose	Example & Notes
Laminin 511-E8	Coating substrate for iPSC maintenance that enhances pluripotency and health.	Defined, xeno-free substrate that improves reproducibility over older matrices like Matrigel.
BMP4	Key morphogen for neural and retinal induction.	Critical for initiating retinal fate; requires precise concentration (e.g., 3 nM) and timing (e.g., DD1-DD3).
Smoothened Agonist (SAG)	Potent activator of the Sonic Hedgehog pathway, crucial for optic vesicle patterning.	Used throughout differentiation protocol to promote retinal identity.
B-27 Supplement Without RA	Serum-free supplement supporting neuronal health and maturation.	The "without RA" version prevents premature differentiation during later stages.
1-Monothioglycerol (1-MTG)	Antioxidant that reduces cellular stress during early aggregation stages.	Helps improve the efficiency of initial retinal cluster formation.
All-Trans Retinoic Acid (RA)	Signaling molecule promoting photoreceptor differentiation and maturation.	Timing of introduction is critical to avoid inhibitory effects on earlier stages.
Taurine	Amino acid that supports photoreceptor development and stability.	Commonly added in maturation phases (e.g., from DD10 onward).
Vitrification Kit	Cryopreservation method for long-term biobanking of organoids.	Superior to slow-freezing for preserving cell viability and nephron (kidney) structural integrity; applicable to retinal organoids [41].

Strategies for Mitigating Variability and Batch Effects

Comprehensive Quality Control and Standardization

A multi-layered QC strategy is essential. This begins with rigorous cell line validation, confirming pluripotency (via markers like OCT4, SOX2) and the presence of desired gene variants via Sanger sequencing before differentiation [40]. Furthermore, implementing standardized differentiation protocols across all lines and batches is non-negotiable. Using defined media and matrices, rather than poorly characterized components like bovine serum, minimizes undefined variables [41]. Finally, establishing a morphological and molecular QC checkpoint around day 30 is crucial. Organoids should be assessed for the formation of optic vesicle-like structures and positive expression of retinal progenitor markers (CHX10, SOX2) to ensure differentiation is on track before proceeding [40].

Advanced Technical Solutions

Incorporating technical innovations can directly address sources of variability. Biobanking and Cryopreservation are powerful tools. Creating master cell banks and large batches of organoids, preserved using optimized methods like vitrification, ensures a consistent, long-term supply of research material and reduces run-to-run variation [41]. For data analysis, employing robust analytical methods that account for batch effects is critical. This includes using experimental designs that randomize samples across processing batches and applying statistical or computational batch-correction methods during the analysis of transcriptional data (e.g., from Nanostring or RNA-seq) [40]. When setting up assays, incorporating internal controls is vital. This involves using standardized reference cell lines (e.g., isogenic controls) in parallel with test lines in every experiment to control for technical noise and allow for normalized comparisons across batches [40] [41].

The derivation of retinal organoids from human pluripotent stem cells (hPSCs) represents a transformative advancement for modeling retinal development, disease, and for therapeutic discovery [11]. However, achieving high-fidelity, laminated retinal tissue with mature photoreceptors in a reproducible and timely manner remains a significant challenge. The protocol variability and extended differentiation timelines, often exceeding 250 days, hinder the broader application of this technology [42]. A critical factor for success lies in the precise optimization of the in vitro microenvironment—specifically, the extracellular matrix, nutrient composition, and strategic supplementation with signaling molecules and other factors. This application note synthesizes current research to provide detailed protocols and data for optimizing these culture conditions, with the overarching goal of establishing a highly reproducible retinal organoid differentiation method.

Essential Research Reagent Solutions

The following table catalogues key reagents identified from recent literature that are crucial for efficient retinal induction, maturation, and the development of clinically compatible protocols.

Table 1: Key Research Reagents for Retinal Organoid Differentiation

Reagent Category	Specific Reagent	Function in Differentiation	Research Context
Extracellular Matrix	Recombinant Laminin 521 (rLN-521) [33] [43]	Xeno-free substrate for hPSC adhesion and retinal differentiation; promotes self-organization.	Critical for clinical-grade, xeno-free protocols.
Extracellular Matrix	Hyaluronan (HA) [44]	Component of native interphotoreceptor matrix; promotes photoreceptor commitment and outer segment maturation.	Improves structural maturity of photoreceptors; polymer molar mass affects outcomes.
Signaling Molecules	Bone Morphogenetic Protein 4 (BMP4) [18] [27] [33]	Directs PSCs toward neuroectoderm and retinal fate during initial induction.	Used briefly (e.g., DD1-DD3) in multiple modern protocols.
Signaling Molecules	Smoothened Agonist (SAG) [18] [27]	Activates Sonic Hedgehog signaling; promotes rapid retinal cell specification and maturation.	Used throughout floating culture or in specific stages to accelerate maturation.
Signaling Molecules	All-trans Retinoic Acid (RA) [18] [27] [45]	Key morphogen for photoreceptor differentiation and maturation.	Timed addition is critical; often supplemented from mid-to-late stages.
Nutrient/Serum Replacement	KnockOut Serum Replacement (KSR) [18] [43]	Defined serum replacement used in early neural induction and differentiation media.	Supports initial stages; part of xeno-free strategies.
Nutrient/Serum Replacement	Human Platelet Lysate (HPL) [33]	Xeno-free supplement providing growth factors and nutrients for long-term culture.	Replaces Fetal Bovine Serum (FBS) in xeno-free protocols.
Small Molecule Inhibitors	IWR-1e [33]	Inhibitor of the WNT signaling pathway; promotes initial cell specification toward retinal fate.	Used in stepwise, small molecule-directed protocols.

Optimized Supplementation and Signaling Pathways

Strategic supplementation with small molecules and growth factors is paramount for guiding retinal fate. The following workflow diagram illustrates the temporal sequence of key signaling pathway manipulations in an accelerated retinal organoid protocol.

Quantitative Analysis of Supplementation Effects

The impact of various supplements on differentiation efficiency and maturation is quantified in the following table, synthesizing data from multiple studies.

Table 2: Quantitative Effects of Key Supplements on Retinal Organoid Development

Supplement	Concentration & Timing	Reported Effect	Protocol Outcome
BMP4 [18] [27]	3 nM, Days 1-3 of differentiation	Directs PSCs toward neuroectoderm and retinal fate.	Foundational step in multiple high-efficiency protocols.
SAG + Activin A + RA [27]	100 nM SAG, 100 ng/mL Activin A, 1 μM RA, Days 10-40	Enables rapid retinal cell specification.	Achieved stage 3 retinal organoids within 90 days.
SAG Alone [27]	100 nM, from Day 40 onward	Supports robust retinal maturation and lamination.	Continued maturation post-specification.
Hyaluronan [44]	Varying molar masses, prolonged treatment	Significant reduction in Ki67+ proliferating cells; increase in CRX+ photoreceptors.	Promoted photoreceptor commitment and mature outer segments with organized discs.
Antioxidants & Lipids [18]	From Day 90 onward	Supports structural maturation of photoreceptors.	Enabled observation of budding calyceal process-like structures by day 140.

Detailed Experimental Protocol: Accelerated Retinal Organoid Differentiation

This protocol is adapted from published methods that successfully generate mature retinal organoids with advanced photoreceptor features within 90-140 days [18] [27].

Materials

• Human iPSC Line: e.g., 1231A3 [18] [27].
• Basal Media: Glasgow's Minimum Essential Medium (GMEM), DMEM/F-12 with GlutaMAX, Advanced DMEM/F-12.
• Essential Supplements: KnockOut Serum Replacement (KSR), N2 Supplement, B27 Supplement without Vitamin A, Fetal Bovine Serum (FBS) or Human Platelet Lysate (HPL), Taurine, Non-essential Amino Acids, Sodium Pyruvate, Penicillin/Streptomycin.
• Signaling Molecules: Recombinant Human BMP4, Smoothened Agonist (SAG), Recombinant Activin A, All-trans Retinoic Acid (RA).
• Small Molecules: 1-monothioglycerol.

Methodologies

Neural Induction and Retinal Specification (Days 0-10)

• Culture iPSCs to form dense colonies in defined feeder-free conditions (e.g., on laminin 511-E8 in StemFit medium) [18].
• Initiate Differentiation (Day 0): Replace maintenance medium with differentiation medium: GMEM supplemented with 10% KSR, 0.1 mM NEAA, 1 mM sodium pyruvate, 1% penicillin/streptomycin, and 450 μM 1-monothioglycerol [18] [27].
• BMP4 Treatment (Days 1-3): Add 3 nM BMP4 to the differentiation medium to direct cells toward retinal fate [18] [27].
• Form Retinal Clusters (Day 10): By day 10, tightly packed retinal clusters should form. Gently scrape and transfer these clusters to a floating culture in maturation medium.

Floating Culture and Photoreceptor Maturation (Day 10 Onward)

• Primary Maturation (Days 10-90): Culture aggregates in Maturation Medium 1 (DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 μM taurine) [18].
  • Days 10-40: Supplement medium with 100 nM SAG, 100 ng/mL Activin A, and 1 μM all-trans RA [18] [27].
  • Days 40-90: Continue with SAG and add B27 supplement without retinoic acid [18].
• Advanced Maturation (Day 90+): Switch to Maturation Medium 2 (Advanced DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 μM taurine) supplemented with SAG and B27 without retinoic acid [18]. For enhanced structural maturation, consider adding antioxidant and lipid supplements as described [18].

Engineering the Microenvironment: Matrix and Physiomimetic Conditions

Beyond biochemical supplementation, the physical and biophysical environment is critical for reproducibility and health of retinal organoids.

Extracellular Matrix Optimization

The transition from animal-derived matrices like Matrigel to defined, xeno-free alternatives is essential for clinical translation. Studies demonstrate that recombinant human laminin 521 (rLN-521) can effectively support the initial adherent culture and differentiation of iPSCs into retinal organoids [33] [43]. Furthermore, the addition of hyaluronan (HA), a native component of the interphotoreceptor matrix, to the culture medium significantly improves photoreceptor differentiation and leads to more mature outer segments with organized disc structures, as validated by transmission electron microscopy [44].

Oxygen Gradients and Microfluidics

The inner retina naturally resides in a hypoxic environment (∼2% O₂), while the outer retina is highly oxygenated (∼18% O₂) [46]. Standard culture conditions do not recapitulate this gradient and often lead to the rapid degeneration of inner retinal cells, such as retinal ganglion cells (RGCs). A novel solution is the use of a PDMS-free retinal organoid chip (ROC) that maintains a physiologically relevant oxygen gradient across the developing organoids [46]. This system has been shown to significantly improve the viability of RGCs in long-term cultures compared to static controls, making it a powerful tool for studying inner retinal diseases and development.

Overcoming Developmental Arrest and Incomplete Maturation

Retinal organoids derived from human pluripotent stem cells (hPSCs) have emerged as a powerful tool for studying human retinogenesis, disease modeling, and drug development. These three-dimensional cellular aggregates differentiate and self-organize to mimic the spatial and temporal patterning of the developing human retina with remarkable fidelity [12]. However, the widespread application of these models, particularly for high-throughput applications, has been hampered by limitations in efficiency and reproducibility, with developmental arrest and incomplete maturation representing significant bottlenecks [12] [47].

A major challenge lies in the inherent variability of differentiation outcomes. Numerous existing retinal induction protocols remain variable in their efficiency and do not routinely produce morphically or functionally mature photoreceptors [48]. This variability is influenced by multiple factors, including cell line-specific differences, the method of embryoid body (EB) formation, and maintenance conditions [48]. Furthermore, comprehensive temporal transcriptome analyses have revealed a significant temporal delay in cell-type-specific gene expression and dysregulation of key signaling pathways in retinal organoids compared to in vivo development [47]. This often results in organoids that lack the functional maturation of distinct cell types, especially photoreceptors, which may fail to develop the sophisticated outer segment structures essential for phototransduction [47] [49].

This Application Note outlines standardized protocols and strategic interventions to overcome these challenges. By addressing critical control points in differentiation, modulating specific signaling pathways, and implementing engineered culture environments, researchers can significantly improve the reproducibility, efficiency, and ultimate maturation of retinal organoids.

Key Challenges in Retinal Organoid Maturation

The journey from pluripotent stem cell to a laminated retinal organoid containing mature, light-responsive photoreceptors is complex and prone to inefficiency. Several critical points have been identified where differentiation can falter:

• Cell Line-Specific Differences: The inherent biological variation between different hPSC lines dominates the variables affecting differentiation efficiency, particularly during the early stages of the process [48].
• EB Generation Method: The technique used to form the initial aggregates—whether mechanical, enzymatic, or dissociation-reaggregation—profoundly impacts the later differentiation and maturation of retinal organoids [48].
• Signaling Pathway Dysregulation: Comparative transcriptome analyses have identified temporal dysregulation of specific signaling pathways during retina development in vitro, leading to altered expression of genes associated with photoreceptor function and survival [47].
• Protocol Manipulation: Extensive tissue manipulation steps, including the transfer of organoids between different culture vessels, render standardization and automation challenging and introduce opportunities for variability [50].

Table 1: Critical Control Points for Improving Retinal Organoid Maturation

Control Point	Challenge	Impact on Maturation
Initial Aggregate Formation	Variable size and shape of EBs leads to inconsistent differentiation.	Regulating organoid size and shape via quick reaggregation improves reproducibility and purity [12].
Early Lineage Specification	Default forebrain fate instead of retinal fate.	Timed activation of BMP signaling directs pure retinal fates at 100% efficiency [12].
Culture Environment	Limitations in nutrient, oxygen, and factor diffusion to organoid core.	Hydrogel-based milliwell arrays promote rapid, efficient generation of retina-like tissue (~93% efficiency) [50].
Photoreceptor Maturation	Delayed or reduced expression of genes for photoreceptor function.	Supplementation with DHA and FGF1 specifically promotes photoreceptor maturation, including cones [47].

Quantitative Assessment of Maturation Status

A clear indicator of maturation success is the emergence and organization of photoreceptors. Advanced protocols have demonstrated the capacity to generate organoids composed of approximately 80% photoreceptors within 26 days, with about 22% of these being GNAT2-positive cones—a rare sensory cell type difficult to study in rodent models [50]. Furthermore, the appearance of an outer plexiform layer (OPL)-like line observed via high-resolution adaptive optics optical coherence tomography (AO-OCT) indicates potential synaptic connectivity between the host/graft bipolar cells and graft photoreceptor cells, suggesting functional integration [51].

Strategic Interventions and Detailed Protocols

Protocol 1: Standardized Differentiation via Modulated Signaling

This protocol focuses on achieving highly reproducible and pure retinal organoid populations by controlling initial aggregate formation and key signaling pathways.

Principle: Regulation of organoid size and shape combined with timed activation of BMP signaling eliminates default forebrain fate and directs differentiation toward retinal lineage with 100% efficiency [12].

Materials:

• hPSCs: Widely used cell lines (e.g., H9, Neo1, AD3) adapted to feeder-free culture [48].
• ROCK Inhibitor (Y-27632): Added for the first 48 hours to increase cell viability post-dissociation [48].
• Basement Membrane Matrix: (e.g., Growth Factor Reduced Matrigel) for coating.
• Retinal Differentiation Media: DMEM-F12 based, supplemented with N2 and B27 [48] [52].

Procedure:

• Culture hPSCs to 90% confluence on GFRM in a defined medium like TeSR1.
• Generate Embryoid Bodies via Dissociation-Reaggregation:
  • Dissociate colonies using a cell detachment solution (e.g., 1 mg/ml collagenase with 0.5 mg/ml dispase).
  • Resuspend cells in TeSR1 with 10 µM ROCK inhibitor (Y-27632).
  • Transfer to bacteriological petri dishes to form floating EBs.
• Induce Neural and Retinal Fate:
  • After 48 hours, change to retinal differentiation media.
  • Activate BMP signaling at a specific, optimized time window to direct retinal fate [12].
• Long-Term Culture and Maturation:
  • Maintain cultures under static or shaking conditions (e.g., 30 rpm orbital shaker).
  • Change media regularly for up to 150 days.
  • For enhanced photoreceptor maturation, add Docosahexaenoic Acid (DHA) and Fibroblast Growth Factor 1 (FGF1) during the maturation phase [47].

Protocol 2: Scalable Production using Hydrogel Milliwell Arrays

This tissue-engineering approach addresses variability by providing a standardized physico-chemical microenvironment for every organoid.

Principle: Arrayed round-bottom milliwells composed of biomimetic poly(ethylene glycol) (PEG) hydrogels promote rapid, efficient, and stereotypical generation of retinal organoids by ensuring consistent aggregate size and overcoming diffusion limitations [50].

Materials:

• PEG-based Hydrogel Milliwell Arrays: 1.5 mm diameter round-bottom cavities.
• mESCs or hPSCs: For example, transgenic mESCs expressing Crx-GFP.
• Supplemented Media: Retinal differentiation media must be optimized with N2 and B27 supplements to overcome predicted local factor shortages [50].

Procedure:

• Fabricate Milliwell Arrays using standard microfabrication strategies to create hydrogels with defined cavities.
• Seed Cells: Seed 21,000 mESCs per macrowell (24-well plate format), containing seven milliwells. Cells will rapidly aggregate into the milliwells.
• Add Extracellular Matrix: 18 hours post-seeding, add basement membrane matrix components to promote neuroepithelial specification.
• Monitor Development: Observe the formation of a neuroepithelial layer by day 3, OV-like structures by day 4, and OC-like structures by day 7.
• Culture Long-Term: Maintain the organoids in the same milliwell arrays with regular media changes, tracking growth and maturation kinetics over time (e.g., 26 days).

This method achieves high efficiency, with ~93% of aggregates developing retinal organoid structures, and allows for reliable single-organoid traceability, which is crucial for high-throughput experimentation [50].

The Scientist's Toolkit: Essential Reagents and Solutions

Table 2: Key Research Reagent Solutions for Retinal Organoid Differentiation

Reagent/Solution	Function & Purpose	Example Usage & Notes
ROCK Inhibitor (Y-27632)	Increases cell survival after dissociation by inhibiting actin-myosin contraction.	Used for the first 48 hours of differentiation during EB formation [48].
BMP Signaling Agonists	Directs early cell fate away from default forebrain and towards retinal lineage.	Timed addition is critical for achieving 100% pure retinal organoid populations [12].
N2 & B27 Supplements	Provide essential nutrients, hormones, and growth factors for neural and retinal survival and maturation.	Crucial for overcoming diffusion limitations in 3D cultures; B27 with vitamin A is used in later stages [50] [52].
Docosahexaenoic Acid (DHA)	A polyunsaturated fatty acid that promotes the maturation and maintenance of photoreceptors.	Added during the maturation phase to improve photoreceptor outer segment biogenesis [47].
Fibroblast Growth Factor 1 (FGF1)	A signaling molecule that supports photoreceptor maturation, particularly cone photoreceptors.	Used in combination with DHA to enhance functional maturation of photoreceptors [47].
Hydrogel Milliwell Arrays	Provides a standardized, biomimetic 3D microenvironment for reproducible aggregate formation and culture.	Enables scalable production and single-organoid traceability; made from PEG [50].
Taurine	An amino acid that may support photoreceptor development and survival.	Used at 100 µM in extended maturation cultures [52].

Visualization of Workflows and Signaling

The following diagrams, created with Graphviz, illustrate the core experimental workflow and the key signaling pathways involved in directing retinal fate.

Experimental Workflow for Standardized Retinal Organoid Differentiation

Diagram 1: A streamlined workflow from hPSCs to mature retinal organoids, highlighting critical steps like aggregate formation and timed BMP activation.

Signaling Pathways in Retinal Fate Specification

Diagram 2: Logical pathway showing how directed signaling (BMP) specifies retinal fate, how dysregulation can lead to maturation arrest, and how specific supplements (DHA/FGF1) can rescue maturation.

Overcoming developmental arrest and incomplete maturation in retinal organoids is achievable through a multi-faceted approach that prioritizes protocol standardization, precise control of developmental signaling, and the implementation of advanced culture technologies. The methods outlined herein—ranging from the regulation of BMP signaling for pure retinal lineage specification to the use of hydrogel milliwell arrays for scalable production and the supplementation with DHA and FGF1 for photoreceptor maturation—provide a robust framework for generating high-quality, reproducible retinal organoids.

By adopting these strategies, researchers can reliably produce retinal tissues that more accurately recapitulate the complexity and functionality of the native human retina. This advancement is critical for unlocking the full potential of retinal organoids in fundamental research, high-throughput drug screening, and the development of future cell-based therapies for blinding retinal diseases.

Achieving high-fidelity structural maturation of photoreceptors in human pluripotent stem cell (hPSC)-derived retinal organoids remains a significant challenge in the pursuit of physiologically relevant in vitro models. A key benchmark for this maturation is the development of specialized subcellular compartments, particularly the outer segments and the calyceal processes (CPs)—microvilli-like structures that extend from the inner segment to ensheath the base of the outer segment in primate photoreceptors [18]. The presence of CPs is critical, as they are enriched with proteins associated with Usher syndrome, and their disruption is implicated in various inherited retinal dystrophies [18]. However, generating retinal organoids with these advanced features typically requires extended culture periods of 180 days or more, which is costly and labor-intensive [18]. This Application Note details an optimized, reproducible differentiation protocol that promotes advanced photoreceptor maturation, including the emergence of budding calyceal process-like structures and organized outer segments, within a shortened timeframe of 140 days [18].

Quantitative Analysis of Photoreceptor Maturation

The following table summarizes the key maturation markers and structural features observed in retinal organoids under the optimized protocol, culminating at day 140.

Table 1: Key Markers of Photoreceptor Maturation in Retinal Organoids

Maturation Feature	Marker/Structure	Expression/Appearance Timeline	Significance
Photoreceptor Commitment	CRX	Emerges by Day 100 [11]	Master regulator of photoreceptor fate and development.
Opsin Expression	RHO (Rhodopsin) & OPSIN	Increase by Day 150 [11]	Indicates functional maturation of phototransduction machinery.
Structural Compartmentalization	Distinct Inner & Outer Segments	Observed by Day 140 [18]	Establishes the polarized architecture essential for phototransduction.
Ciliary Connection	Connecting Cilia	Observed by Day 140 [18]	Forms the critical transport link between the inner and outer segments.
Periciliary Architecture	Budding Calyceal Process-like Structures	Observed by Day 140 [18]	A hallmark of advanced maturation, critical for structural stability and associated with Usher protein localization.

Reagent Solutions for Reproducible Retinal Organoid Differentiation

A core requirement for reproducibility is the use of defined reagents. The table below lists essential materials used in the featured protocol and the field in general.

Table 2: Research Reagent Solutions for Retinal Organoid Differentiation

Reagent Category	Specific Product	Function in Protocol
Cell Line	Human iPSC line (e.g., 1231A3) [18]	Starting patient-specific material capable of self-renewal and differentiation into all retinal cell types.
Basal Medium	Glasgow’s Minimum Essential Medium (GMEM); DMEM/F-12 [18] [53]	Provides the foundational nutrients and salts for cell survival and growth.
Serum Replacement	KnockOut Serum Replacement (KSR); Fetal Bovine Serum (FBS) [18] [53]	Provides a defined, consistent supplement of growth factors and proteins to support differentiation.
Induction Factor	Bone Morphogenetic Protein 4 (BMP4) [18] [11]	Directs cells toward retinal fate during early differentiation stages.
Maturation Supplements	Smoothened Agonist (SAG), Activin A, all-trans Retinoic Acid (RA) [18]	Promotes hedgehog signaling, supports photoreceptor maturation, and provides essential chromophore precursor.
Xeno-Free Substrate	Recombinant Human Laminin 521 (rhLN-521) [53]	A defined, clinical-grade substrate for iPSC attachment and growth, replacing animal-derived matrices.

Detailed Experimental Protocol

This section outlines the step-by-step methodology for generating structurally mature retinal organoids, adapted from the optimized protocol [18].

Materials

• Cell Source: Human induced pluripotent stem cells (iPSCs) [18].
• Maintenance Medium: StemFit medium on Laminin 511-E8 coated plates [18].
• Differentiation Media:
  • Differentiation Medium: GMEM supplemented with 10% KSR, 0.1 mM Non-essential Amino Acids, 1 mM Sodium Pyruvate, 450 µM 1-monothioglycerol [18].
  • Maturation Medium 1: DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 µM taurine [18].
  • Maturation Medium 2: Advanced DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 µM taurine [18].
• Key Supplement Factors: BMP4, SAG, Activin A, all-trans Retinoic Acid, B-27 supplement without retinoic acid [18].

Step-by-Step Procedure

Diagram Title: Retinal Organoid Differentiation Workflow

• iPSC Pre-culture: Seed human iPSCs at a density of 5,000 cells/well in a 6-well plate coated with Laminin 511-E8. Culture in StemFit medium for 10 days until dense colonies form, changing the medium every other day [18].
• Differentiation Initiation (DD0): On differentiation day 0, replace the StemFit medium with Differentiation Medium [18].
• Retinal Fate Induction (DD1-DD3): Add 3 nM BMP4 to the Differentiation Medium for a 3-day period to direct cells toward a retinal fate [18] [11].
• Formation of 3D Organoids (DD10): On day 10, gently scrape the tightly packed retinal clusters that have formed at the bottom of the dish and transfer them to a low-cell-adhesion plate to initiate floating culture in Maturation Medium 1 [18].
• Early Maturation (DD10-DD40): Culture the floating organoids in Maturation Medium 1 supplemented with 100 nM SAG, 100 ng/mL Activin A, and 1 µM all-trans Retinoic Acid. Refresh the medium every 3-4 days [18].
• Mid-Term Maturation (DD40-DD90): Continue culture in Maturation Medium 1, but now supplement only with 100 nM SAG and B-27 supplement without retinoic acid. Refresh the medium every 3-4 days [18].
• Advanced Maturation (DD90-DD140): Switch the culture medium to Maturation Medium 2, supplemented with 100 nM SAG and B-27 supplement without retinoic acid. Maintain the organoids in this medium, with regular feeding, until day 140 [18]. Organoids are now ready for analysis of mature photoreceptor structures.

Pathway and Structural Analysis

The maturation of photoreceptors is a tightly regulated process. The following diagram illustrates the key signaling pathways manipulated in the protocol and the resulting mature photoreceptor structure.

Diagram Title: Signaling Pathways and Photoreceptor Maturation

Key Pathway Manipulations

• BMP4 Signaling: Added during the initial differentiation phase to robustly direct iPSCs toward a retinal fate, ensuring a high yield of retinal progenitor cells [18] [11].
• Hedgehog Pathway Activation: The Smoothened Agonist (SAG) is used throughout the maturation phases to promote the proliferation and differentiation of retinal progenitors, particularly photoreceptors [18].
• Retinoic Acid (RA) Signaling: The timed addition of all-trans Retinoic Acid is critical for the expression of opsins and the formation of the outer segment, as RA is a key derivative of Vitamin A used in the visual cycle [18].

Analysis of Mature Structures

At day 140, organoids can be analyzed for advanced features via immunohistochemistry and electron microscopy.

• Immunohistochemistry: Confirm the presence of all major retinal cell types and layered organization using markers like CRX (photoreceptors), VSX2 (bipolar cells), and BRN3A (ganglion cells) [11] [54]. Staining for Usher proteins (e.g., USH2A, WHRN) can validate their localization to the calyceal processes [18].
• Electron Microscopy: This is essential for visualizing the ultrastructural hallmarks of maturity, including the distinct inner and outer segments, the connecting cilium, and, most notably, the budding calyceal process-like structures that project from the inner segment [18] [54].

The adoption of human pluripotent stem cell (hPSC)-derived retinal organoids in basic research, disease modeling, and drug screening has been hampered by limitations in efficiency and reproducibility. Individual organoids often exhibit broad variability in size, shape, and cellular composition, making direct comparisons across experiments challenging [4]. This application note details a standardized framework of quality control metrics and experimental protocols, developed within a broader thesis on highly reproducible retinal organoid differentiation, to ensure batch-to-batch consistency suitable for high-throughput and preclinical applications.

Key Quantitative Quality Control Metrics

Implementing a robust quality control system requires tracking quantitative metrics from the earliest stages of differentiation through to mature organoids. The following tables summarize critical benchmarks for assessing efficiency, structural maturity, and functional maturation.

Table 1: Efficiency and Early-Stage Quality Control Metrics

Quality Metric	Target Benchmark	Measurement Method	Protocol/Reference
Aggregate Size Uniformity	Consistent 2D area and circularity at Day 3 and 6 [4]	Bright-field imaging and image analysis (e.g., circularity index) [4]	Standardized reaggregation in U-bottom plates [4]
Retinal Specification Efficiency	100% of aggregates expressing retinal lineage markers (e.g., SIX6:GFP) [4]	Fluorescence imaging or immunostaining for SIX6, RAX, CHX10 at D14-D20 [4] [55]	Seeding 1,000-8,000 cells/well with BMP4 modulation [4]
Retinal Domain Formation	High yield of retinal domains (e.g., 65 ± 27 per differentiation) [35]	Manual counting of translucent, pigmented neural epithelia [35]	BMP4 supplementation on day 6 of differentiation [35]

Table 2: Mid- to Late-Stage Maturation and Purity Metrics

Quality Metric	Target Benchmark	Measurement Method	Protocol/Reference
Photoreceptor Precursor Emergence	Robust CRX+ and Recoverin+ cell layers by D60-D100 [55] [18]	Immunostaining of cryosections [55] [18]	Long-term maturation culture with serum, taurine, and T3 [55]
Photoreceptor Structural Maturation	Appearance of inner/outer segments and calyceal processes by D140 [18]	Transmission electron microscopy, immunohistochemistry for Usher proteins [18]	Antioxidant and lipid supplementation in maturation medium [18]
Metabolic Maturity Shift	Shift in f/b NADH ratio indicating metabolic transition, stabilization by 4 months [56]	Two-photon fluorescence lifetime imaging microscopy (FLIM) [56]	Non-invasive live monitoring of organoid metabolism [56]
Off-Target Tissue Assessment	Minimal to no cortex-like or spinal cord-like tissue [55]	qPCR-based assay for non-retinal markers [55]	Dissection and qPCR analysis of peripheral tissue sheets [55]

Detailed Experimental Protocols for Quality Control

Protocol: Standardized Generation of Retinal Organoids via Quick Reaggregation

This protocol is designed to minimize initial variability by ensuring consistent aggregate size and shape, forming the foundation for reproducible retinal organoid differentiation [4].

Key Materials:

• hPSCs: Human embryonic stem cells (e.g., H7, H9) or induced pluripotent stem cells (e.g., PGP1, 1231A3) [4] [18].
• ROCK Inhibitor (Y-27632): To increase cell viability after single-cell dissociation [48] [55].
• Low-Adhesion 96-Well U-Bottom Plates: For forced reaggregation of cells into uniformly sized aggregates [4] [55].
• BMP4: Directs cells toward retinal fate when applied during a specific temporal window [4] [55] [35].

Procedure:

• Culture and Preconditioning: Maintain hPSCs in a feeder-free system (e.g., on laminin-511/E8 in StemFit medium) [55] [18]. Precondition cells with 10 µM Y-27632 for 18-30 hours prior to differentiation to enhance survival.
• Single-Cell Dissociation and Seeding: On Day 0, enzymatically dissociate hPSC colonies into a single-cell suspension. Count cells and seed them into low-adhesion 96-well U-bottom plates at a defined density of 2,000 cells per well in differentiation medium (e.g., gfCDM + KSR) supplemented with 10 µM Y-27632 and 100 nM SAG [4] [55]. Centrifuge the plates to encourage immediate aggregation.
• BMP4 Treatment for Retinal Specification: On Day 1-3, add 1.5-3 nM BMP4 to the culture medium to direct the aggregates toward a retinal fate [4] [55] [35]. Omission of BMP4 can completely block retinal specification, providing a critical control [4].
• Early Aggregate Handling and Long-Term Culture: On Day 1-2, transfer aggregates to larger low-adhesion dishes (e.g., 45-48 aggregates per 10 cm dish) in retinal differentiation medium. Gently agitate the plates every 2-3 days to prevent fusion. Continue with protocol-specific maturation steps, which may include timed treatment with CHIR99021, SU5402, all-trans retinoic acid, and taurine to promote photoreceptor maturation and lamination [55] [18].

Quality Control Checkpoint: At Day 3 and Day 6, use bright-field imaging to confirm that aggregates are uniform in size and shape. At Day 14-20, assess the expression of early retinal markers like SIX6, RAX, or CHX10 via immunostaining to confirm retinal specification has occurred with high efficiency [4].

Protocol: qPCR-Based Quality Control for Tissue Selection

This quality control protocol is essential for identifying and selecting pure retinal tissue for downstream applications, especially transplantation therapy [55].

Key Materials:

• qPCR Reagents: Primers for retinal-specific markers (e.g., CHX10, CRX) and off-target tissue markers (e.g., cortical marker FOXG1, spinal cord marker HOXB4) [55].
• Tissue Preservation Medium: For short-term storage of tissue sheets during QC analysis [55].

Procedure:

• Dissection: At the appropriate stage (e.g., day 60-100), dissect the 3D organoid into two tissue sheets: an inner-central sheet (candidate for transplantation/final product) and an outer-peripheral sheet (for QC analysis) [55].
• RNA Extraction and qPCR: Isolve the outer-peripheral sheet and extract mRNA. Perform qPCR using a pre-validated panel of markers.
• Analysis and Selection: Compare the expression profile of the QC sample against established benchmarks. The inner-central sheet is only advanced for transplantation or critical experiments if the QC sample shows high expression of retinal markers (CHX10, CRX) and negligible expression of off-target markers (FOXG1, HOXB4) [55].
• Tissue Preservation: During the qPCR process (typically 3-4 days), store the inner-central sheet in a validated preservation medium to maintain tissue viability [55].

Protocol: Non-Invasive Functional Maturation Assessment via 2-Photon Microscopy

This protocol utilizes live imaging to monitor the metabolic and structural maturation of retinal organoids without the need for fixation, allowing for longitudinal studies and quality control of the same organoid over time [56].

Key Materials:

• Two-Photon Microscope: Equipped for fluorescence lifetime imaging (FLIM) and hyperspectral imaging (HSpec) [56].
• Specialized Objective: e.g., Plan-Apochromat 20x/0.8 objective [56].

Procedure:

• Organoid Preparation: Transfer a live retinal organoid to a suitable imaging chamber with culture medium.
• Fluorescence Lifetime Imaging (FLIM): Image the organoid using a two-photon laser (e.g., 740 nm excitation). Collect the fluorescence decay of intrinsic NADH. Analyze the data using the phasor approach to calculate the free/bound NADH ratio, a proxy for the metabolic state (glycolysis vs. oxidative phosphorylation) [56].
• Hyperspectral Imaging (HSpec): Using the same microscope, collect the full emission spectrum for each pixel in the image. Use phasor analysis to identify specific molecular signatures, such as the presence of retinol, a marker of functional photoreceptor cells [56].
• Longitudinal Tracking: Perform these imaging sessions at monthly intervals from month 2 to month 6 of differentiation. A quality-controlled batch should show a metabolic shift toward oxidative phosphorylation (decreasing f/b NADH ratio) between the second and third months, stabilizing from the fourth month onward, coinciding with the emergence of retinol signal [56].

Quality Control Workflow and Signaling Pathways

A successful quality control strategy integrates standardized protocols with specific signaling pathway modulation and checkpoints at critical developmental stages. The following diagram illustrates the logical workflow from initial aggregation to mature, validated retinal organoids.

The efficacy of this workflow hinges on the precise modulation of key signaling pathways. The following diagram summarizes the role of the primary pathways involved in directing retinal fate and promoting maturation.

The Scientist's Toolkit: Research Reagent Solutions

A selection of essential reagents and their critical functions in achieving high-quality, reproducible retinal organoids is provided below.

Table 3: Essential Research Reagents for Reproducible Retinal Organoid Differentiation

Reagent Category	Specific Example(s)	Function in Differentiation	Key References
Signaling Modulators	BMP4	Directs neural epithelium toward retinal fate versus default forebrain fate when applied early.	[4] [55] [35]
	SAG (Smoothened Agonist)	Activates Sonic Hedgehog signaling; enhances survival of neural cells.	[55] [35]
	DAPT (γ-secretase inhibitor)	Inhibits Notch signaling; increases photoreceptor yield.	[35]
Maturation Supplements	All-Trans Retinoic Acid (RA)	Promotes photoreceptor maturation and opsins expression.	[35] [18]
	Taurine & T3 (Thyroid Hormone)	Supports photoreceptor survival and maturation.	[55]
	Docosahexaenoic Acid (DHA)	Fatty acid that promotes photoreceptor structural maturation and outer segment biogenesis.	[18] [47]
Culture Aids	ROCK Inhibitor (Y-27632)	Improves cell survival after passaging and single-cell dissociation.	[48] [55]
	Synthemax / Laminin-511	Defined, xenogeneic-free extracellular matrix for feeder-free hPSC culture.	[55] [57]
	KnockOut Serum Replacement (KSR)	Defined serum replacement used in early differentiation media.	[55] [18]

Validation and Comparative Analysis of Retinal Organoid Models

Core Principles of Molecular Validation for Retinal Organoids

Molecular validation is a critical step for confirming the identity, maturity, and reproducibility of human pluripotent stem cell (hPSC)-derived retinal organoids. This process moves beyond simple marker expression to provide a comprehensive quantitative assessment of how closely an in vitro model recapitulates in vivo human retinogenesis. The core principle involves comparative analysis against established reference data from human fetal and adult retinas, enabling researchers to objectively determine the differentiation status and cellular composition of their organoid cultures [58]. This approach is particularly valuable for addressing the substantial variability observed between different stem cell lines and differentiation protocols, thereby improving reproducibility across laboratories [58] [59].

Key molecular dimensions for validation include bulk and single-cell transcriptomics to map cell-type specification and developmental trajectories, marker expression analysis via immunohistochemistry to verify spatial organization and protein-level expression, and increasingly, multi-omic integrations that combine transcriptomic data with epigenetic information such as chromatin accessibility [60] [36]. This multi-faceted validation strategy establishes a rigorous framework for evaluating retinal organoid quality, which is essential for reliable disease modeling, drug screening, and the assessment of experimental therapies such as AAV-based gene delivery [61].

Experimental Protocols and Workflows

Transcriptome-Based Molecular Staging

This protocol utilizes bulk RNA sequencing to benchmark retinal organoids against human fetal and adult retinal transcriptomes, providing an objective measure of developmental maturity [58].

• Sample Collection: Collect retinal organoids at multiple time points throughout differentiation (e.g., days 40, 90, 150, 200, 260) [62]. Include replicates from different hPSC lines and differentiation batches to assess variability.
• RNA Extraction and Sequencing: Homogenize individual organoids in TRIzol reagent. Extract total RNA and assess quality using a Bioanalyzer. Prepare sequencing libraries (e.g., poly-A selected) for Illumina short-read sequencing to a minimum depth of 30 million reads per sample [58] [62].
• Bioinformatic Analysis:
  • Alignment and Quantification: Align sequenced reads to the human reference genome (GRCh38) using STAR aligner and quantify gene-level counts with featureCounts.
  • Comparative Analysis: Perform correlation analysis, principal component analysis (PCA), and differential expression testing comparing organoid transcriptomes to publicly available datasets of human fetal and adult retina [58] [63].
  • Developmental Staging: Use correlation coefficients with fetal reference data to assign a "molecular stage" to each organoid, effectively determining its equivalent gestational week [58].

Single-Cell RNA Sequencing (scRNA-seq) for Lineage Reconstruction

scRNA-seq deconvolutes cellular heterogeneity and reconstructs developmental trajectories, enabling the validation of rare cell populations and lineage bifurcations [63].

• Single-Cell Suspension Preparation:
  • Pool 4-5 retinal organoids per time point.
  • Dissociate with Accutase for 30 minutes at 37°C with gentle agitation.
  • Quench enzyme activity with FBS-containing medium.
  • Filter through a 35-μm cell strainer and centrifuge to pellet [63].
• Cell Sorting (Optional): For enriching specific lineages, use Fluorescence-Activated Cell Sorting (FACS). For example, sort BLIMP1-EGFP+ cells to isolate the photoreceptor lineage [63].
• Library Preparation and Sequencing: Process cells through a single-cell platform (e.g., 10x Genomics Chromium) using a 3' gene expression kit. Sequence libraries on an Illumina HiSeq platform to a target of 50,000 reads per cell [63].
• Data Processing and Analysis:
  • Pre-processing: Use Cell Ranger (version 3.1+) to align reads to GRCh38 and generate a feature-barcode matrix.
  • Clustering and Annotation: Perform analysis in Seurat (version 4.0+). Normalize data, identify highly variable genes, perform PCA, and cluster cells using a graph-based approach. Annotate cell types by mapping clusters to reference datasets (e.g., human fetal retina from GSE138002) and known marker genes [63].
  • Trajectory Inference: Utilize tools like Monocle3 or Slingshot to reconstruct pseudotemporal ordering of cells along differentiation pathways, such as the progression from retinal progenitor cells (RPCs) to cones and rods [63].

Single-Cell Multi-Omics Profiling (scRICA-seq)

The single-cell RNA isoform and chromatin accessibility sequencing (scRICA-seq) method simultaneously profiles full-length RNA isoforms and open chromatin in the same cell, revealing regulatory dynamics [60].

• Nuclei and Cytoplasmic RNA Isolation: For low-throughput samples, use a nuclear-cytoplasmic separation method to obtain nuclei (for ATAC-seq) and cytoplasmic RNA (for isoform sequencing) from the same cell [60].
• scRCAT-seq2 for Isoform Sequencing:
  • End Labeling and Circularization: Label ends of individual RNA/cDNA molecules with a Unique Molecular Identifier (UMI). Create circular cDNA through end-to-end ligation.
  • Amplification and Fragmentation: Perform circular amplification to generate multiple copies of full-length cDNA. Fragment the cDNA randomly using Tn5 transposase.
  • Library Construction and Sequencing: Construct libraries from the fragmented products and perform paired-end sequencing. Integrate short reads with the same UMI to reconstruct full-length isoforms, covering transcription start sites (TSS), transcription end sites (TES), and specific exons [60].
• scATAC-seq in Parallel: Process the isolated nuclei using a standard scATAC-seq protocol to generate a library of accessible chromatin regions [60].
• Integrated Data Analysis: Co-embed the transcriptomic and epigenomic data to identify associations between chromatin accessibility at promoters or enhancers and the expression of specific isoforms of fate-determining genes (e.g., NRL, CRX, THRB) [60].

Immunohistochemical Validation of Marker Expression

Protein-level validation is essential to confirm transcriptomic findings and assess spatial organization and cellular morphology.

• Tissue Fixation and Sectioning:
  • Fix whole retinal organoids in 4% paraformaldehyde for 1 hour at room temperature.
  • Cryoprotect by incubating in a sucrose gradient (10-30%).
  • Embed organoids in OCT compound and freeze.
  • Section at a thickness of 10 μm using a cryostat [58] [62].
• Immunofluorescence Staining:
  • Permeabilize and block sections with a solution of 3% BSA and 0.1% Triton X-100 in PBS for 1 hour.
  • Incubate with primary antibodies diluted in blocking buffer overnight at 4°C.
  • Wash and incubate with appropriate fluorescently-labeled secondary antibodies for 1 hour at room temperature.
  • Counterstain nuclei with DAPI or Hoechst and mount slides [62] [63].
• Imaging and Analysis: Acquire high-resolution images using a confocal microscope (e.g., Leica or Zeiss LSM800). Use consistent exposure settings across samples. Analyze images for co-localization of markers and layer formation using Fiji/ImageJ [63].

Key Data and Validation Metrics

The tables below summarize expected outcomes and key reagents for the molecular validation of retinal organoids.

Table 1: Key Transcriptomic and Cellular Markers for Validating Retinal Organoids

Cell Type / Stage	Key Markers (RNA/Protein)	Expected Onset (Approx. Day of Differentiation)	Validation Method	Function/Notes
Retinal Progenitor Cells (RPCs)	VSX2 (CHX10), PAX6, RAX, SOX2 [58] [61] [64]	Day 25-35 [61] [64]	scRNA-seq, IHC, qPCR	Multipotent progenitors; form neuroepithelium.
Retinal Ganglion Cells (RGCs)	ISL1, PAX6, GAP43, BRN3 [60] [64]	Day 32-50 [64]	IHC, scRNA-seq	First neuronal cell type to be specified.
Photoreceptor Precursors	CRX, OTX2, BLIMP1 [63]	Day 45-70 [64]	scRNA-seq, IHC (including reporter lines)	Common post-mitotic precursor for rods and cones.
Cone Photoreceptors	ARR3, PDE6H, THRB, OPSINS [60]	After day 100 [60]	IHC, scRNA-seq	Emerge before rods in human development.
Rod Photoreceptors	NRL, RHODOPSIN, NR2E3 [58] [63]	After day 120 [58]	IHC, Immunoblot, scRNA-seq	9-cis retinal accelerates maturation and rhodopsin expression [58].
Mature Bipolar Cells	VSX1, PRKCA [64]	After day 160 [64]	scRNA-seq, IHC	Later-born inner nuclear layer neurons.

Table 2: Essential Research Reagent Solutions for Molecular Validation

Reagent / Tool Category	Specific Examples	Function / Application
Cell Lines & Reporters	H9 hESCs (WA09), patient-derived iPSCs, BLIMP1-EGFP reporter line [58] [62] [63]	Provide a consistent genetic background; enable live tracking and FACS enrichment of specific lineages (e.g., photoreceptors).
Critical Growth Factors & Small Molecules	BMP-4, IGF1, 9-cis Retinal, all-trans Retinoic Acid (ATRA), Taurine, FBS [58] [63]	Direct differentiation and promote maturation. 9-cis retinal is more effective than ATRA for rod maturation [58].
Key Antibodies for IHC	Anti-VSX2, Anti-PAX6, Anti-CRX, Anti-ISL1, Anti-ARR3, Anti-RHO [58] [61] [63]	Protein-level validation of key retinal cell types and assessment of spatial organization in organoid sections.
Sequencing Kits & Platforms	10x Genomics Chromium Single Cell 3' Kit, Illumina sequencing platforms, SIRV spike-in controls [60] [63]	Generate transcriptomic and epigenomic data; spike-ins assess sensitivity and accuracy of isoform detection [60].
Bioinformatic Tools	Seurat, Cell Ranger, Monocle3, Azimuth (for cell-type annotation) [59] [63]	Process and analyze single-cell data, perform cell-type annotation, and reconstruct developmental trajectories.

The Scientist's Toolkit: Visualization of Signaling Pathways

The following diagrams illustrate key signaling pathways and experimental workflows critical for retinal organoid development and validation.

IGF1-PHLDA1 Signaling in Photoreceptor Development

Diagram 1: The IGF1-PHLDA1-pAKT axis regulates human photoreceptor specification. IGF1 signaling through its receptor (IGF1R) upregulates PHLDA1 expression, which in turn inhibits AKT phosphorylation, thereby promoting photoreceptor cell fate [63].

Multi-omic Experimental Workflow (scRICA-seq)

Diagram 2: The scRICA-seq workflow for simultaneous profiling of chromatin accessibility and RNA isoforms from the same single cell. This integrated approach reveals correlations between the epigenome and transcriptome during retinal neuronal fate determination [60].

Robust molecular validation through transcriptomic profiling and marker expression analysis is indispensable for establishing retinal organoids as reproducible and physiologically relevant models. The integration of bulk and single-cell RNA sequencing with protein-level spatial data and emerging multi-omic technologies provides an unprecedented, multi-dimensional view of human retinogenesis in vitro. Adherence to standardized protocols and rigorous benchmarking against in vivo reference data, as Artel dep into the underlying biology of retinal development and disease, these comprehensive validation frameworks will be crucial for translating organoid-based discoveries into meaningful therapeutic advances for blinding disorders.

Retinal organoids (ROs) derived from human pluripotent stem cells (hPSCs) represent a transformative model for studying retinal development, disease, and therapeutic interventions [54]. A critical milestone in their maturation is the establishment of functional competence, specifically the ability to replicate the human retina's native phototransduction cascade and electrophysiological properties [65]. This protocol details the methodologies for assessing these functional parameters, providing a standardized framework for evaluating ROs within the context of highly reproducible differentiation research. The ability to generate consistent, light-responsive ROs is paramount for their application in disease modeling, drug screening, and cell replacement therapies [39].

Key Functional Properties for Assessment

A comprehensive functional assessment of ROs must verify the presence of three critical, interconnected properties essential for a robust light response.

• Photoreceptor Ion Channel Membrane Properties: The membrane properties of photoreceptors indicate their potential functionality. The presence of specific ionic channels, including cyclic nucleotide-gated (CNG) channels in the outer segment and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, is requisite for maintaining membrane potential and modulating phototransduction signals [65].
• A Functional Phototransduction Cascade: This biochemical pathway begins when a photon interacts with an opsin in the photoreceptor's outer segment. The cascade must be intact, culminating in a change in neurotransmitter release at the synaptic terminal [65].
• Synaptic Connectivity: Functional synaptic connections between photoreceptors and downstream neurons (horizontal and bipolar cells) in the inner nuclear layer are the final requirement for signal transduction through the retinal layers [65].

Experimental Protocols for Functional Assessment

This section provides detailed methodologies for key experiments used to evaluate the functional maturity of ROs.

Electrophysiology

1. Patch-Clamp Recording

• Objective: To characterize the electrophysiological properties and light-induced responses of individual photoreceptors and other retinal neurons within the organoid.
• Procedure:
  • Preparation: Transfer a mature RO (typically >D120) to a recording chamber continuously perfused with oxygenated Ames' medium at 32-35°C.
  • Visualization: Use infrared differential interference contrast (IR-DIC) video microscopy to target specific cells for recording.
  • Recording: Obtain whole-cell patch-clamp configurations on target cells using borosilicate glass electrodes.
  • Stimulation:
    • For voltage-gated currents, apply a series of voltage steps from a holding potential.
    • For light responses, deliver light stimuli of varying intensities and wavelengths via a light-emitting diode (LED) source focused through the microscope condenser.
  • Data Analysis: Analyze membrane capacitance, resistance, and light-evoked changes in current or membrane potential.

2. Multielectrode Array (MEA) Recording

• Objective: To monitor network-level activity and light responses from multiple cells simultaneously across the organoid.
• Procedure:
  • Preparation: Place a single RO on an MEA chip pre-coated with a cell-adhesion molecule (e.g., poly-D-lysine).
  • Acclimation: Allow the organoid to settle in the recording chamber with perfused medium for at least 30 minutes.
  • Recording: Extracellularly record spontaneous and light-evoked action potentials and local field potentials from multiple electrodes.
  • Stimulation: Present full-field light flashes of different durations, intensities, and frequencies.
  • Data Analysis: Analyze spike rates, waveforms, and response latencies to assess network functionality and signal propagation.

Calcium Imaging

1. Objective: To visualize intracellular calcium flux as a proxy for neuronal activation in response to light stimulation. 2. Procedure: 1. Loading: Incubate ROs with a cell-permeable fluorescent calcium indicator (e.g., Cal-520 AM or Fluo-4 AM) for 45-60 minutes. 2. Washing: Rinse thoroughly to remove excess dye. 3. Imaging: Transfer the RO to a confocal or two-photon microscope with an environmental chamber. Capture time-lapse images at a high frame rate. 4. Stimulation: During imaging, deliver controlled light stimuli. 5. Data Analysis: Quantify changes in fluorescence intensity (ΔF/F0) in regions of interest (ROIs) corresponding to individual cells or layers. An increase in signal indicates a calcium influx upon cellular activation.

Electroretinography (ERG) on Organoids

1. Objective: To measure summed electrical responses of multiple retinal cell types to light flashes, mimicking clinical ERG. 2. Procedure: 1. Setup: A custom apparatus is required. The RO is placed in a recording chamber between two electrodes. 2. Recording: The organoid is stimulated with a brief light flash, and the transtissue electrical potential is recorded. 3. Analysis: The resulting waveform is analyzed for key components analogous to the in vivo ERG, such as the a-wave (photoreceptor response) and b-wave (bipolar cell response) [65].

Immunohistochemistry and Molecular Analysis

1. Objective: To validate the structural and molecular basis of function. 2. Procedure: 1. Fixation: Fix ROs in 4% paraformaldehyde. 2. Sectioning: Embed and cryosection organoids (e.g., using the high-throughput HistoBrick method [39]). 3. Staining: Perform immunofluorescence staining for key functional markers: * Synaptic Connectivity: Antibodies against PSD95, RIBEYE, Bassoon, SV2, and Piccolo. * Photoreceptor Maturation: Antibodies against rhodopsin (rod opsins), L/M/S-opsins (cone opsins), and PCARE (connecting cilium/outer segment). 4. Imaging: Acquire high-resolution images using confocal or super-resolution microscopy to confirm proper localization of proteins in outer segments and synaptic zones.

Quantitative Data and Functional Markers

The following tables summarize key quantitative benchmarks and markers for assessing RO function.

Table 1: Key Maturation Markers for Functional Assessment

Marker Category	Specific Marker	Localization/Function	Significance for Function
Phototransduction	Rhodopsin (RHO)	Rod Outer Segment	Visual pigment for scotopic vision [38].
	L/M/S-Opsins	Cone Outer Segment	Visual pigments for photopic/color vision [38].
	Recoverin (RCVRN)	Photoreceptor Cytoplasm	Calcium-binding protein; modulator of phototransduction [38].
	Arrestin (SAG)	Photoreceptor Cytoplasm/O.S.	Terminates the phototransduction cascade [65].
Synaptic Function	PSD95	Post-synaptic Density (Photoreceptor)	Scaffolding protein in the OPL [65].
	RIBEYE (CtBP2)	Pre-synaptic Ribbon (Photoreceptor)	Core component of the synaptic ribbon [65].
	SV2	Synaptic Vesicles	Synaptic vesicle glycoprotein [65].
Ion Channels	CNGA1 (CNG Channel)	Photoreceptor Outer Segment	Mediates photocurrent; final step in phototransduction [65].
	HCN1	Photoreceptor Inner Segment	Contributes to membrane properties and response kinetics [65].

Table 2: Expected Functional Outcomes from Assessment Techniques

Assessment Technique	Measured Parameter	Expected Outcome in Mature ROs
Patch-Clamp Recording	Light-evoked current	Outer Segments: Hyperpolarization and suppression of inward current in rods/cones [65].
	Membrane channels	Recordings of CNG and HCN channel activity [65].
Calcium Imaging	ΔF/F0 in INL cells	Increased calcium flux in second-order neurons (e.g., bipolar cells) post-light stimulus, indicating synaptic transmission [65].
Multielectrode Array (MEA)	Spike rate / Bursting	Altered firing patterns in RGCs in response to light; correlated network activity [65].
Electroretinography (ERG)	a-wave amplitude	Robust negative deflection indicating photoreceptor activity [65].
	b-wave amplitude	Robust positive deflection indicating bipolar cell activity [65].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents and Materials for Functional Assessment

Item	Function/Application	Example/Note
hPSC Lines	Starting material for RO differentiation.	Use of well-characterized iPSC or ESC lines is critical for reproducibility [54].
Neural Induction Media	Directs pluripotent stem cells toward a neural and retinal fate.	Often contains DMEM/F12, N2/B27 supplements, and small molecules like IWR1e (WNT inhibitor) [38].
Retinal Differentiation Media	Supports the maturation and layer formation of the neural retina.	Often contains taurine, retinoic acid, and reduced serum (e.g., switching from 10% to 5% KSR) to promote photoreceptor genesis [38].
Calcium-Sensitive Dyes	For functional calcium imaging of neuronal activity.	Cell-permeable AM esters, e.g., Cal-520 AM, Fluo-4 AM [65].
Viral Vectors (AAV/LV)	For cell-type-specific labeling or genetic manipulation.	e.g., AAV5 with cell-specific promoter (e.g., cone-specific) to express GFP for live imaging in screening assays [39].
Synaptic Marker Antibodies	Immunohistochemical validation of synaptic connectivity.	e.g., Anti-PSD95, Anti-RIBEYE (CtBP2), Anti-SV2 [65].
Photoreceptor Marker Antibodies	Immunohistochemical validation of photoreceptor maturation and outer segment formation.	e.g., Anti-Rhodopsin, Anti-Opsin (Red/Green, Blue), Anti-PCARE [38] [65].
Agarose Microwell Arrays	Standardizes embryoid body formation, improving RO reproducibility and yield [39].	Used during initial stages of differentiation to control aggregate size.
HistoBrick Mold	High-throughput histological processing of organoids [39].	Enables parallel sectioning of multiple organoids in a single block, preserving spatial identity.

Workflow and Signaling Pathway Diagrams

Phototransduction Cascade Pathway

The following diagram illustrates the molecular cascade in rod photoreceptors, which leads to a hyperpolarizing response to light. This pathway is a key indicator of functional maturity in retinal organoids.

Functional Assessment Workflow

This diagram outlines the logical sequence of experiments for comprehensively evaluating the functional status of retinal organoids.

Comparative Analysis with Traditional 2D Cultures and Animal Models

The study of human retinal development and disease has long relied on traditional two-dimensional (2D) cell cultures and animal models. However, these systems possess significant limitations for translational research. Two-dimensional cultures of immortalized human retinal cells lack the cellular diversity, spatial organization, and cell-cell interactions of native retinal tissue, while animal models, particularly rodents, fail to fully recapitulate human retinal disease due to species differences and the absence of a macula, a key feature of the human retina responsible for high-acuity vision [66] [67]. These constraints have hampered our understanding of retinal disease mechanisms and the development of effective therapeutics.

The advent of human pluripotent stem cell (hPSC)-derived three-dimensional (3D) retinal organoids (ROs) represents a paradigm shift in ophthalmic research. These complex, self-organizing structures closely mimic the spatial and temporal patterning of the developing human retina, providing unprecedented access to human-specific retinogenesis and disease pathology [4] [66]. This Application Note provides a comparative analysis of these model systems, details a highly reproducible protocol for retinal organoid generation, and outlines their application in disease modeling and drug discovery.

Comparative Analysis of Retinal Model Systems

The following table summarizes the key characteristics of traditional and emerging retinal model systems, highlighting the unique advantages of retinal organoids.

Table 1: Comparative Analysis of Retinal Model Systems

Feature	Traditional 2D Cultures	Animal Models (e.g., Rodents)	3D Retinal Organoids
Cellular Architecture	Monolayer; lacks 3D organization and lamination [66]	Native 3D laminated architecture; lacks a macula [66] [67]	Multilayered, self-organizing structure mimicking native retinal lamination [66] [14]
Cellular Diversity	Limited; often only one or a few cell types [66]	Complete, but with species-specific ratios (e.g., rod-dominated) [67]	Contains all major retinal cell types, including human-specific photoreceptors [35] [14]
Human Disease Relevance	Low; lacks human genetic and physiological context [66]	Moderate; valuable but limited by species differences in pathophysiology [66] [67]	High; patient-derived iPSCs capture human genetic background for modeling diseases [66] [67]
Throughput for Screening	High	Low to moderate	Moderate; improving with protocol standardization [4] [66]
Key Limitations	Does not recapitulate tissue physiology or complex interactions [66]	Inadequate for modeling macular diseases and some human-specific disease phenotypes [66] [67]	Variability in differentiation efficiency and maturation timelines; lack of vascularization [48] [66] [67]

A Highly Reproducible Method for Retinal Organoid Differentiation

Recent advances have focused on standardizing differentiation protocols to maximize efficiency and minimize variability. A 2024 study demonstrated that by regulating organoid size and shape through forced reaggregation of singularized cells, retinal organoids can be generated with 100% efficiency and significantly greater reproducibility in size, shape, and cellular composition across multiple hPSC lines [4].

Standardized Protocol for High-Efficiency Retinal Organoid Generation

Key Principle: Traditional methods using proteolytic enzymes (e.g., dispase) to release hPSC colonies result in aggregates of variable size and shape, leading to inconsistent differentiation outcomes. This protocol overcomes this by generating aggregates of consistent size and shape from defined single-cell suspensions [4].

Materials:

• Human pluripotent stem cells (hPSCs)
• Low-adhesion 96-well U-bottom plates
• Retinal differentiation media

Workflow:

• hPSC Dissociation: Enzymatically dissociate hPSC colonies into a single-cell suspension.
• Forced Reaggregation: Seed defined cell numbers (e.g., 2,000 cells/well) into low-adhesion 96-well U-bottom plates. Centrifuge to form uniform aggregates.
• Early-Stage Culture (Days 0-6): Maintain aggregates in plates to prevent fusion, gently agitating every 2-3 days.
• Retinal Specification (Day 6): Activate BMP signaling by adding 1.5 nM BMP4 to the medium to direct cells toward a retinal fate with 100% purity [4] [35].
• Long-Term Maturation: Transfer aggregates to larger culture dishes under gentle agitation for continued differentiation and maturation over several months.

This standardized method yields highly pure populations of retinal organoids with expedited differentiation timelines compared to traditional methods [4]. The following diagram illustrates this optimized workflow.

Figure 1: Standardized Workflow for Retinal Organoid Differentiation

Quantitative Outcomes of Improved Differentiation Methods

The impact of protocol optimization is evident in quantitative improvements in efficiency and yield. The table below compares different methodological approaches.

Table 2: Impact of Differentiation Method on Retinal Organoid Yield and Composition

Differentiation Method	Key Modifications	Reported Efficiency / Yield	Key Cellular Outcomes
Traditional 3D (Method 1) [35]	Wnt inhibition (IWR-1e); Hedgehog agonist (SAG); Notch inhibition (DAPT)	12.3 ± 11.2 retinal domains per differentiation [35]	Lower photoreceptor yield at day 85; proper maturation by day 200 [35]
Traditional 3D-2D-3D (Method 2) [35]	Minimal extrinsic inductive cues	6.3 ± 6.7 retinal domains per differentiation [35]	Lower photoreceptor yield at day 85; proper maturation by day 200 [35]
Enhanced 3D-2D-3D with BMP4 (Method 3) [35]	Addition of BMP4 at day 6 of differentiation	65 ± 27 retinal domains per differentiation [35]	Significantly more photoreceptors and ganglion cells at day 85; expression of mature rod/cone markers by day 200 [35]
Standardized Size-Controlled Method [4]	Forced reaggregation; defined aggregate size; BMP activation	100% efficiency across multiple cell lines [4]	Highly reproducible size/shape; expedited differentiation; pure populations of retinal cells [4]

Signaling Pathways Guiding Retinal Fate

The directed differentiation of hPSCs into retinal organoids requires precise manipulation of key developmental signaling pathways. The successful specification of retinal versus forebrain fate, as demonstrated in the standardized protocol, hinges on the timed activation of BMP signaling [4]. Furthermore, comparative transcriptome analyses have identified other pathways that are dysregulated in organoids compared to in vivo development, providing targets for further improvement [47].

Figure 2: Key Signaling Pathways in Retinal Organoid Development

The Scientist's Toolkit: Essential Reagents for Retinal Organoid Research

Table 3: Key Research Reagent Solutions for Retinal Organoid Differentiation

Reagent / Material	Function in Differentiation	Example Usage
BMP4	Directs neural epithelium toward retinal pigment epithelium and retinal fates; crucial for achieving pure populations of retinal organoids [4] [35].	Added at day 6 of differentiation at 1.5 nM to specify retinal fate with 100% efficiency [35].
ROCK Inhibitor (Y-27632)	Enhances cell survival after dissociation by inhibiting actin-myosin contraction; reduces apoptosis in early aggregates [48].	Supplemented in media for the first 48 hours following dissociation and reaggregation [48].
Wnt Inhibitors (e.g., IWR-1e, DKK-1)	Promotes anterior neural fate and retinal specification by inhibiting the Wnt/β-catenin pathway, which posteriorizes neural tissue [35] [67].	Used in initial differentiation phases (e.g., days 0-7) to induce retinal differentiation [35].
Extracellular Matrix (Matrigel)	Provides a basement membrane scaffold that supports the growth and polarization of retinal progenitor cells during adherent culture phases [48] [35].	Used to coat plates for the initial 2D adherent phase in 3D-2D-3D protocols [35].
Docosahexaenoic Acid (DHA) & FGF1	Promotes the functional maturation of photoreceptors, including outer segment biogenesis and synaptic formation, addressing a key deficiency in organoid cultures [67] [47].	Added during later maturation stages (e.g., after day 100) to enhance photoreceptor maturity [47].
Low-Adhesion U-Bottom Plates	Enables the formation of uniformly-sized cellular aggregates via forced reaggregation, critical for protocol reproducibility [4].	Used at day 0 to seed defined numbers of singularized hPSCs for standardized embryoid body formation [4].

The evolution of retinal organoid technology represents a significant advancement over traditional 2D cultures and animal models for studying the human retina. By implementing standardized protocols that control initial aggregate size and modulate key signaling pathways like BMP, researchers can now generate highly reproducible and pure populations of retinal organoids. These 3D models, which closely mimic the cellular composition and architecture of the native human retina, are already enabling more accurate disease modeling and hold immense promise for accelerating drug discovery and development for debilitating retinal diseases. Continued efforts to further improve maturation, incorporate vascular elements, and standardize functional assays will solidify the role of organoids as an indispensable tool in both basic and translational ophthalmic research.

Retinoblastoma (RB) is the most common primary intraocular malignancy in childhood, with an incidence of approximately 1 in 16,000 to 18,000 live births [68]. While approximately 98% of retinoblastomas are initiated by biallelic inactivation of the RB1 tumor suppressor gene, a distinct and aggressive subtype—accounting for 1–2% of unilateral cases—is characterized by MYCN oncogene amplification in the absence of RB1 mutations [69] [70]. This MYCN-amplified RB1 wild-type (MYCNampRB1+/+) retinoblastoma presents a unique therapeutic challenge, typically diagnosed at a very early age (often before 12 months) and demonstrating aggressive clinical behavior with poor differentiation and potential treatment resistance [69] [71].

The study of MYCN-driven retinoblastoma has been hampered by limitations of conventional models. Traditional retinoblastoma cell lines (e.g., Y79, WERI-Rb1) lack the three-dimensional cytoarchitecture and cellular heterogeneity of the developing retina, while genetically engineered mouse models often require additional genetic alterations beyond RB1 loss and may not fully recapitulate human disease [71]. The development of human pluripotent stem cell (hPSC)-derived retinal organoids has provided a transformative platform that faithfully mimics human retinal development, enabling investigation of tumor initiation within a context that recapitulates the spatial and temporal patterning of the human retina [71] [33].

This case study details the application of an advanced retinal organoid differentiation protocol to model MYCN-amplified retinoblastoma, defining a critical developmental window of susceptibility and identifying subtype-specific therapeutic vulnerabilities. The integrated methodologies and findings presented herein establish a robust framework for targeted therapeutic discovery in this aggressive pediatric cancer.

Background and Clinical Significance

MYCN-amplified retinoblastoma represents a distinct molecular subtype with characteristic clinical and histopathological features. Patients with this subtype typically present with unilateral disease at an early age (median age of diagnosis approximately 9 months), often exhibiting advanced intraocular disease requiring enucleation [69]. Histopathologically, these tumors demonstrate a distinctive bland morphology with cells containing round nuclei and frequent large nucleoli, typically lacking the rosette or fleurette differentiation patterns seen in conventional retinoblastoma [69].

From a molecular perspective, MYCN is a member of the MYC family of transcription factors that regulates crucial cellular processes including proliferation, differentiation, and apoptosis. During normal retinal development, MYCN plays an essential role in maintaining the proliferative capacity of retinal progenitor cells. However, when overexpressed or amplified, MYCN drives uncontrolled proliferation and impaired differentiation, particularly in RB1-proficient contexts [71].

The clinical management of MYCN-amplified retinoblastoma presents specific challenges. Genomic analysis of aqueous humor-derived cell-free DNA has emerged as a valuable diagnostic approach for identifying MYCN amplification, providing critical information for treatment planning [69]. Furthermore, recent advances in MRI-based radiomics show promise for non-invasive differentiation of MYCNampRB1+/+ tumors from RB1-/- retinoblastomas based on morphological features such as lower sphericity, higher flatness, and greater gray-level heterogeneity [70]. These diagnostic innovations are particularly important given the contraindication of tumor biopsy in retinoblastoma due to risks of tumor seeding and metastasis.

Retinal Organoid Differentiation Platform

Highly Reproducible Retinal Organoid Generation

The foundation of this modeling approach is a highly reproducible and efficient method for generating retinal organoids from human pluripotent stem cells. This protocol achieves 100% efficiency in producing pure populations of retinal organoids across multiple widely used cell lines through timed activation of BMP signaling and regulation of organoid size and shape using quick reaggregation methods [12] [72]. The standardized protocol significantly reduces variability compared to traditional methods and accelerates the differentiation timeline, making it suitable for high-throughput applications including disease modeling and drug screening [72].

Key advancements in this protocol include the elimination of time-consuming manual microdissection steps through the implementation of an agarose micromould platform that generates uniform self-assembled 3D spheres from dissociated hPSCs in microwells [33]. This approach enables scalable production of retinal organoids while maintaining reproducibility. Additionally, xeno-free conditions have been established by substituting Matrigel and fetal bovine serum with recombinant laminin and human platelet lysate, respectively, facilitating future clinical translation [33].

Enhanced Photoreceptor Maturation

Recent protocol refinements have enabled the generation of retinal organoids exhibiting advanced photoreceptor maturation within 140 days, a significant improvement over traditional methods requiring 180 days or more [18]. These enhanced organoids display compartmentalized photoreceptor architecture with distinct inner and outer segments, connecting cilia, and—notably—budding calyceal process-like structures that were previously unattainable in stem cell-derived photoreceptors [18].

Table 1: Key Reagents for Retinal Organoid Differentiation

Research Reagent	Function in Protocol	Application Context
Recombinant Laminin-521	Extracellular matrix substrate for hPSC attachment	Replacement for Matrigel in xeno-free conditions
BMP4 (3 nM)	Directs cells toward retinal fate	Added from differentiation days 1-3
Smoothened Agonist (SAG)	Activates SHH signaling pathway	Promotes retinal differentiation from day 10
All-trans Retinoic Acid	Promotes photoreceptor differentiation	Added during maturation phase
Human Platelet Lysate	Serum substitute with human growth factors	Xeno-free culture conditions
N2 & B27 Supplements	Provides essential nutrients and hormones	Supports neural and retinal differentiation

This improved structural maturation is crucial for modeling retinal diseases and particularly valuable for investigating the developmental context of retinoblastoma, which originates during fetal retinal development. The ability to generate organoids with advanced photoreceptor features within a shortened culture timeframe addresses a major limitation in the field and enables more physiologically relevant disease modeling [18].

Experimental Modeling of MYCN-Amplified Retinoblastoma

Stage-Dependent Tumorigenesis

To elucidate the developmental context of MYCN-driven retinoblastoma, retinal organoids were transduced with lentiviral vectors encoding MYCN-GFP at three distinct developmental windows: early (days 40-70), intermediate (days 70-120), and late (days 120-150) [71]. The incidence of tumor formation was strongly dependent on the developmental stage at which MYCN was overexpressed, with the intermediate stage (70-120 days) showing significantly higher susceptibility to transformation [71].

Table 2: Tumor Formation Frequency by Developmental Stage

Developmental Stage	Days Post-Differentiation	Tumor Formation Incidence
Early	40-70	25% (5 of 20 organoids)
Intermediate	70-120	80% (24 of 30 organoids)
Late	120-150	43.5% (10 of 23 organoids)

Immunofluorescence analysis revealed that the tumor-like structures consisted of highly proliferative cells expressing the retinal progenitor marker SOX2 but lacking the photoreceptor commitment marker CRX, indicating that MYCN promotes tumorigenesis by maintaining cells in a proliferative, undifferentiated progenitor-like state while preventing photoreceptor differentiation [71]. This finding was corroborated by co-localization analysis showing significant positive correlation between MYCN-GFP signal and both Ki-67 (PCC = 0.59) and SOX2 (PCC = 0.64), but negligible correlation with CRX (PCC = 0.02) [71].

Figure 1: MYCN Oncogenic Signaling Pathway. MYCN overexpression drives tumorigenesis by sustaining proliferation while blocking differentiation, maintaining retinal progenitor cells in a proliferative state.

Molecular Characterization

Transcriptomic profiling of MYCN-overexpressing organoids demonstrated close recapitulation of molecular features observed in patient-derived MYCN-amplified retinoblastomas. Specifically, these models showed activation of MYC/E2F and mTORC1 signaling pathways, consistent with the known roles of MYCN in cell cycle progression and metabolic regulation [71]. The molecular profile further supported the premise that MYCN drives tumorigenesis through dysregulation of normal retinal developmental programs.

The MYCN-overexpressing cells (MYCNO/E-cells) isolated from these organoids demonstrated functional tumorigenicity when xenografted into immunodeficient NOD-SCID mice, forming prominent intraocular tumors resembling leukocoria within two months post-injection [71]. This established the validity of the organoid-derived model for in vivo therapeutic studies and confirmed the tumorigenic potential of MYCN-driven cells in an orthotopic context.

Therapeutic Vulnerability Screening

Pharmacological Profiling

Pharmacological screening of MYCN-overexpressing retinal organoids identified distinct therapeutic vulnerabilities compared to conventional RB1-deficient retinoblastoma models. The MYCN-driven cells demonstrated particular sensitivity to transcriptional inhibitors (THZ1, Flavopiridol) and the cell-cycle inhibitor Volasertib, indicating a unique oncogene-addicted state [71]. This subtype-specific sensitivity pattern suggests that MYCN-amplified retinoblastomas may be vulnerable to targeted therapies that differ from those effective against RB1-deficient tumors.

The enhanced sensitivity to transcriptional inhibitors aligns with the known dependency of MYC-driven cancers on ongoing transcription, revealing a potential therapeutic strategy specifically for this aggressive retinoblastoma subtype. This finding has significant clinical implications, as conventional chemotherapeutic approaches for retinoblastoma (typically involving carboplatin, etoposide, and vincristine) may have limited efficacy against MYCN-amplified cases [68].

Table 3: Drug Sensitivity Profiling in MYCN vs. RB1-Deficient Models

Therapeutic Agent	Mechanism of Action	Efficacy in MYCN Models	Efficacy in RB1-/- Models
THZ1	Transcriptional inhibitor (CDK7/12 targeting)	High sensitivity	Lower sensitivity
Flavopiridol	Transcriptional inhibitor (pan-CDK inhibitor)	High sensitivity	Moderate sensitivity
Volasertib	Cell cycle inhibitor (PLK1 targeting)	High sensitivity	Variable response
Conventional Chemotherapy (CEV)	DNA damage & microtubule disruption	Limited efficacy	Standard of care

Clinical Correlations and Diagnostic Applications

The identification of MYCN amplification as a driver of aggressive retinoblastoma behavior has important diagnostic implications. Analysis of aqueous humor-derived cell-free DNA has emerged as a valuable liquid biopsy approach for identifying MYCN amplification in retinoblastoma patients [69]. In one case series, genomic analysis of aqueous humor revealed MYCN amplification with 23 copies of the oncogene in a patient's tumor, while blood showed the normal 2 copies [69]. This non-invasive diagnostic approach provides critical information for treatment planning, particularly when considering conservative versus aggressive management strategies.

Additionally, MRI-based radiomics has shown promise for non-invasive differentiation of MYCNampRB1+/+ retinoblastoma from the conventional RB1-/- subtype. A recent multicenter case-control study developed a prediction model using T2-weighted MR images that achieved a mean AUC of 0.78, with features including lower sphericity, higher flatness, and greater gray-level heterogeneity predictive for MYCN-amplified status [70]. This imaging-based classification approach could facilitate earlier identification of this aggressive subtype without invasive procedures.

Research Protocols and Methodologies

Retinal Organoid Differentiation Protocol

Protocol Title: Highly Efficient Retinal Organoid Differentiation from Human Pluripotent Stem Cells

Key Reagents and Equipment:

• Human pluripotent stem cells (hPSCs)
• Recombinant laminin-521 (for xeno-free conditions)
• BMP4 (3 nM)
• Smoothened agonist (SAG, 100 nM)
• All-trans retinoic acid (1 μM)
• Agarose micromould platform (for scalable production)
• Maturation medium (DMEM/F-12 with N2 supplement, B27 supplement without retinoic acid, and taurine)

Procedure:

• Maintenance Culture: Culture hPSCs in StemFit medium on laminin 511-E8 fragment-coated plates until formation of dense colonies.
• Differentiation Initiation: Replace culture medium with differentiation medium consisting of Glasgow's Minimum Essential Medium (GMEM) supplemented with 10% KnockOut Serum Replacement, non-essential amino acids, sodium pyruvate, and 1-monothioglycerol.
• Retinal Specification: Add BMP4 (3 nM) from differentiation days 1-3 to direct cells toward retinal fate.
• Retinal Cluster Formation: On day 10, gently scrape tightly packed retinal clusters and transfer to floating culture in Maturation Medium 1 supplemented with SAG, activin A, and all-trans retinoic acid.
• Photoreceptor Maturation: From day 40, culture in Maturation Medium 1 with SAG and B27 supplement without retinoic acid.
• Advanced Maturation: From day 90, switch to Maturation Medium 2 (Advanced DMEM/F-12 with GlutaMAX, fetal bovine serum, N2 supplement, and taurine) with continued SAG and B27 supplementation.

Quality Control:

• Verify retinal specification by immunohistochemical analysis for PAX6 and VSX2 at week 9.
• Confirm photoreceptor differentiation by CRX and RECOVERIN expression by week 17.
• Assess advanced maturation by emergence of inner/outer segment structures and calyceal process-like structures by day 140 [18].

MYCN Overexpression and Tumor Modeling Protocol

Protocol Title: Modeling MYCN-Driven Retinoblastoma in Retinal Organoids

Key Reagents:

• Lentiviral vectors encoding MYCN-GFP
• Polybrene (8 μg/mL)
• Puromycin (for selection)
• Immunodeficient NOD-SCID mice (for xenograft validation)

Procedure:

• Developmental Staging: Determine optimal transduction window based on organoid developmental stage (days 70-120 for maximal susceptibility).
• Lentiviral Transduction: Transduce retinal organoids with lentiviral vectors encoding MYCN-GFP or GFP-only control using polybrene enhancement.
• Selection and Expansion: Apply puromycin selection (if using constructs with resistance markers) and monitor for GFP expression.
• Tumor Formation Monitoring: Observe organoids for focal, aggressively expanding neoplastic growths characterized by disrupted architecture.
• Cell Line Establishment: Isolate GFP-positive tumor regions and culture in suspension to establish stable MYCN-overexpressing cell lines (MYCNO/E-cells).
• In Vivo Validation: Perform orthotopic subretinal injections of MYCNO/E-cells into immunodeficient NOD-SCID mice to confirm tumorigenic potential.

Analytical Methods:

• Immunofluorescence for Ki-67 (proliferation), SOX2 (retinal progenitor), and CRX (photoreceptor commitment)
• Transcriptomic profiling for MYC/E2F and mTORC1 pathway activation
• Pharmacological screening using transcriptional inhibitors and cell cycle targets

Figure 2: Experimental Workflow for Modeling MYCN-Amplified Retinoblastoma. The process begins with retinal organoid differentiation from hPSCs, followed by MYCN transduction during the susceptible developmental window, resulting in tumor organoids suitable for molecular and therapeutic analysis.

This case study demonstrates the powerful application of advanced retinal organoid technologies for modeling the developmental origins and therapeutic vulnerabilities of MYCN-amplified retinoblastoma. The identification of a discrete developmental window (days 70-120) during which retinal progenitors show heightened susceptibility to MYCN-driven transformation provides crucial insights into the ontogeny of this aggressive subtype. Furthermore, the discovery of distinct sensitivities to transcriptional and cell-cycle inhibitors reveals a unique oncogene-addicted state that may be exploited therapeutically.

The methodologies presented establish a robust and reproducible platform for investigating retinoblastoma pathogenesis and screening potential therapeutics, with particular value for rare subtypes where traditional model systems have proven inadequate. Future applications of this platform may include high-throughput compound screening, investigation of combination therapies, and exploration of resistance mechanisms—all within a human-derived, physiologically relevant context that closely mimics the developing retina.

The integration of these organoid technologies with diagnostic advances in liquid biopsy and radiomics promises to accelerate the development of personalized approaches for retinoblastoma management, potentially improving outcomes for patients with this aggressive pediatric cancer. As retinal organoid protocols continue to advance, achieving even greater morphological maturity and cellular diversity, these models will undoubtedly yield further insights into retinal development and disease.

Benchmarking Against Clinical Phenotypes and Patient-Derived Tissues

The pursuit of a highly reproducible differentiation method for retinal organoids is paramount for their effective application in disease modeling and drug development. A significant challenge in the field is the substantial variability in the efficiency and outcomes of existing protocols [48]. This variability can be attributed to several critical factors, including the specific methods used for embryoid body (EB) formation, the background of the pluripotent stem cell line employed, and the maintenance conditions throughout the long differentiation process [48] [35]. This protocol application note addresses these challenges by benchmarking organoid outputs against clinical phenotypes and authentic patient-derived tissues, providing a framework for assessing the fidelity and reproducibility of differentiation methods.

Quantitative Benchmarking of Differentiation Protocols

A direct comparison of established differentiation methods reveals significant differences in yield, cellular composition, and maturation timelines, which are crucial for selecting a protocol for reproducible research.

Table 1: Comparison of Retinal Organoid Differentiation Method Outcomes

Method Characteristic	3D Method (e.g., Wahlin et al.)	3D-2D-3D Method (e.g., Zhong et al.)	3D-2D-3D with BMP4 (e.g., Kuwahara et al.)
Protocol Basis	Serum-free EB quick aggregation [35]	Minimal extrinsic cues for autonomous differentiation [35]	Adaptation of 3D-2D-3D with early BMP4 exposure [35]
Retinal Domain Yield	12.3 ± 11.2 [35]	6.3 ± 6.7 [35]	65 ± 27 [35]
Key Small Molecules	IWR-1e (Wnt inhibitor), SAG (Hedgehog agonist), DAPT (Notch inhibitor) [35]	Not specified in results	BMP4 (Directed retinal fate) [18] [35]
Photoreceptor Yield (Day 85)	Moderate CRX+ cells [35]	Moderate CRX+ cells [35]	Significantly more CRX+ cells [35]
Notable Features	Uses inhibitors and agonists to guide differentiation [35]	Relies on self-organization	High yield and accelerated photoreceptor development [35]

Furthermore, the maturation stage of the organoids must be benchmarked against standardized criteria to evaluate their advanced structural development accurately.

Table 2: Staging and Maturation Benchmarks for Retinal Organoids

Developmental Stage	Timeline (Approx.)	Key Morphological and Molecular Markers	Benchmarking against Clinical Phenotypes
Early Stage	Differentiation days 30-50 [54]	Well-defined neuroepithelial margin; presence of NPCs and RGCs [54]	Recapitulates early human eye development [54]
Mid Stage	Differentiation days 80-120 [54]	Development of a dark-phase core; emergence of early cone and rod photoreceptor progenitors [54]	Models the onset of human retinal diseases [54]
Advanced Maturation (Beyond Stage 3)	Differentiation days 120-180+ [18] [54]	Compartmentalized inner/outer segments; connecting cilia; budding calyceal process-like structures; expression of Usher proteins [18]	Represents structurally mature tissue for modeling ciliopathies (e.g., Usher syndrome, LCA) [18]
Accelerated Protocol (MG/FF)	~32 days for RGCs [64]	Defined layer of ISL-1+/PAX6+ ganglion cells by day 32 [64]	Useful for modeling ganglion cell pathologies like glaucoma [64]

Detailed Experimental Protocols for Reproducible Differentiation

Protocol 1: High-Yield Differentiation with BMP4 Supplementation

This protocol is adapted from Kuwahara et al. and Capowski et al., demonstrating high efficiency in generating retinal organoids [18] [35].

• Initial Cell Culture: Maintain human iPSCs (e.g., line 1231A3) in StemFit medium on plates coated with laminin 511-E8 fragment [18].
• Differentiation Initiation (Day 0): Replace the maintenance medium with differentiation medium: Glasgow’s Minimum Essential Medium (GMEM) supplemented with 10% KnockOut Serum Replacement (KSR), 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 450 µM 1-monothioglycerol [18].
• BMP4 Treatment (Days 1-3): Add 1.5 - 3 nM Bone Morphogenetic Protein 4 (BMP4) to the differentiation medium to direct cells toward retinal fate [18] [35].
• Floating Culture and Patterning (Day 10): Gently scrape the formed, tightly packed retinal clusters and transfer them to a floating culture in "Maturation Medium 1" (DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 µM taurine). From day 10 to day 40, supplement the medium with 100 nM Smoothened Agonist (SAG), 100 ng/mL activin A, and 1 µM all-trans retinoic acid (RA) [18].
• Long-term Maturation (Day 40+): From day 40 to day 90, continue culture in Maturation Medium 1 with SAG and B27 supplement without retinoic acid. After day 90, switch to "Maturation Medium 2" (Advanced DMEM/F-12 with GlutaMAX, 10% FBS, N2 supplement, 100 µM taurine) with SAG and B27 supplement without retinoic acid for the remainder of the culture period [18]. Organoids can be maintained for over 140 days to achieve advanced maturation [18].

Protocol 2: Influencing Early Differentiation through Embryoid Body Formation

This methodology systematically compares EB formation techniques, a critical early variable influencing reproducibility [48].

• Mechanical EB Formation:
  • Grow hiPSCs to 90% confluence.
  • Manually score colonies into fragments (~1.4 mm²) using a sterile pipette tip.
  • Dislodge fragments with a cell scraper and transfer to bacteriological petri dishes in medium with 10 µM Y-27632 (ROCKi) for the first 48 hours. This method was found to produce the most consistent retinal tissue [48].
• Enzymatic EB Formation:
  • Treat hiPSC colonies with collagenase/dispase solution for 30-45 minutes until detached.
  • Collect detached colonies, wash, and resuspend in petri dishes with medium ± ROCKi for 48 hours [48].
• Dissociation–Reaggregation EB Formation:
  • This is a modified version of the Eiraku et al. protocol, which typically involves fully dissociating cells and reaggregating them in low-attachment plates [48] [35].
• Subsequent Culture Conditions: After EB formation, cultures can be maintained under static (stationary) or dynamic (shaking on an orbital shaker) conditions throughout the differentiation process, with the latter often improving nutrient exchange [48].

The Scientist's Toolkit: Essential Reagents for Retinal Organoid Differentiation

Table 3: Research Reagent Solutions for Retinal Organoid Differentiation

Reagent Category	Specific Examples	Function in Differentiation
Basal Media	GMEM, DMEM/F-12, Advanced DMEM/F-12 [18]	Provide essential nutrients and salts as the foundation for culture media.
Supplements	KnockOut Serum Replacement (KSR), N2 Supplement, B27 Supplement (without retinoic acid), Fetal Bovine Serum (FBS) [18] [35]	Supply hormones, proteins, and micronutrients to support cell survival and neural/retinal specification.
Small Molecule Inducers	BMP4 [18] [35], Smoothened Agonist (SAG) [18] [35], all-trans Retinoic Acid (RA) [18] [35], IWR-1e (Wnt inhibitor) [35], DAPT (Notch inhibitor) [35]	Direct cell fate by activating or inhibiting key signaling pathways involved in retinal development.
Survival & Maturation Aids	Y-27632 (ROCKi) [48], Taurine [18], 1-Monothioglycerol (anti-oxidant) [18]	Enhance cell survival after passaging/dissociation and promote structural maturation of photoreceptors.
Extracellular Matrix	Matrigel [35], Laminin 511-E8 [18]	Provide a substrate for cell attachment and growth, influencing polarization and organization.

Signaling Pathways Guiding Retinal Differentiation

The stepwise differentiation of pluripotent stem cells into retinal organoids requires the precise temporal manipulation of key evolutionary conserved signaling pathways to mimic in vivo development.

Conclusion

The development of highly reproducible retinal organoid differentiation methods represents a transformative advancement in ocular research, enabling unprecedented consistency and efficiency in generating human-relevant retinal models. By standardizing protocols through precise control of signaling pathways, organoid size, and culture conditions, researchers can now achieve 100% efficiency in retinal fate specification with significantly reduced differentiation timelines. These improvements address critical bottlenecks in high-throughput applications, making retinal organoids increasingly viable for disease modeling, drug screening, and personalized medicine approaches. The rigorous validation of these models through molecular profiling, functional assessment, and therapeutic vulnerability identification confirms their fidelity to human retinal development and disease pathology. Future directions should focus on further enhancing structural maturation, incorporating vascularization, and developing standardized quality metrics to facilitate clinical translation. As these technologies continue to evolve, they promise to accelerate the development of novel therapies for currently untreatable retinal degenerative diseases, bridging the gap between basic research and clinical application in ophthalmology.

References

• 1. Retinal Organoids: Innovative Tools for Understanding ... [https://www.mdpi.com/1422-0067/26/7/3263]
• 2. Progress of iPSC-derived retinal organoids in the study of ... [https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-04059-7]
• 3. “Armed in-vitro retina”-generating microglial retinal ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1574283/full]
• 4. A highly reproducible and efficient method for retinal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11194494/]
• 5. Retinal organoid differentiation from iPSCs cultured in the ... [https://www.takarabio.com/learning-centers/stem-cell-research/technical-notes/organoids/retinal-organoid-differentiation-from-ipscs-cultured-in-the-cellartis-def-cs-500-culture-system?srsltid=AfmBOorkAfPpk0VyuXc99hBDzTwIi-3CLKGYS_CtXsnXrry_mWUzRyQa]
• 6. Generation of vascularized retinal organoids containing ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12513421/]
• 7. Transplantation of derivative retinal organoids from ... [https://www.nature.com/articles/s41536-024-00387-7]
• 8. Organoids for the Study of Retinal Development and ... [https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2021.667880/full]
• 9. Self-Organization of the Retina during Eye Development ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9221005/]
• 10. Retinal Organoids: Advances in Generation, Development ... [https://www.intechopen.com/online-first/1203712]
• 11. Retinal Organoids: Innovative Tools for Understanding Retinal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11990004/]
• 12. A highly reproducible and efficient method for retinal organoid ... [https://pubmed.ncbi.nlm.nih.gov/38870053/]
• 13. Retinal Organoids: A Next-Generation Platform for High- ... [https://link.springer.com/article/10.1007/s12015-023-10661-8]
• 14. Cell Types of the Human Retina and Its Organoids at ... [https://www.sciencedirect.com/science/article/pii/S0092867420310047]
• 15. Human organoids in basic research and clinical applications [https://www.nature.com/articles/s41392-022-01024-9]
• 16. A highly reproducible and efficient method for retinal ... [https://ohsu.elsevierpure.com/en/publications/a-highly-reproducible-and-efficient-method-for-retinal-organoid-d]
• 17. Reproducibility and staging of 3D human retinal organoids ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6340149/]
• 18. Improved Differentiation of Human Retinal Organoids ... [https://www.mdpi.com/2674-1172/4/4/27]
• 19. Retinal organoid differentiation methods determine organoid cellular ... [https://jtggjournal.com/article/view/4287]
• 20. A look into retinal organoids: methods, analytical techniques, and applications | Cellular and Molecular Life Sciences [https://link.springer.com/article/10.1007/s00018-021-03917-4]
• 21. Generation and Staging of Human Retinal Organoids ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.732382/full]
• 22. Human iPSC-derived retinal organoids develop robust ... [https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2024.1340448/full]
• 23. Robust generation of photoreceptor-dominant retinal ... [https://www.sciencedirect.com/science/article/pii/S2213671125000293]
• 24. Advancements, Strategies, and Challenges in Organoid ... [https://www.sciencedirect.com/science/article/pii/S2095809925006083]
• 25. Functional Study of the BMP Signaling Pathway in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12383973/]
• 26. Bone morphogenetic protein (BMP) signaling determines ... [https://www.nature.com/articles/s41467-025-57185-y]
• 27. Rapid and efficient generation of mature retinal organoids ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11315325/]
• 28. Sonic Hedgehog signaling in spinal cord injury [https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2025.1624501/full]
• 29. Sonic Hedgehog signaling in spinal cord injury [https://pubmed.ncbi.nlm.nih.gov/40808911/]
• 30. Human macula formation involves two waves of retinoic ... [https://www.sciencedirect.com/science/article/pii/S2213671125002516]
• 31. Rapid and efficient generation of mature retinal organoids ... [https://tus.elsevierpure.com/en/publications/rapid-and-efficient-generation-of-mature-retinal-organoids-derive/]
• 32. Bioengineering Human Pluripotent Stem Cell-Derived Retinal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9653705/]
• 33. Generation of 3D retinal tissue from human pluripotent ... [https://www.nature.com/articles/s41598-022-10540-1]
• 34. Retinogenesis in a Dish: Bibliometric Analysis and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10695087/]
• 35. Retinal organoid differentiation methods determine ... [https://www.oaepublish.com/articles/jtgg.2021.35]
• 36. Multimodal spatiotemporal phenotyping of human retinal ... [https://www.nature.com/articles/s41587-023-01747-2]
• 37. Three‐dimensional tissue engineering and organoid ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12617557/]
• 38. A look into retinal organoids: methods, analytical techniques ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8558279/]
• 39. Retinal Organoids Offer Hope for Vision Therapies [https://www.technologynetworks.com/cell-science/articles/high-throughput-retinal-organoids-a-new-vision-for-therapy-development-402789]
• 40. Development of a three-dimensional organoid model to ... [https://www.nature.com/articles/s41598-023-40382-4]
• 41. Organoids in disease modeling and regenerative medicine [https://pmc.ncbi.nlm.nih.gov/articles/PMC12011692/]
• 42. Determining Essential Factors Required for Expediting ... [https://www.jyi.org/2025-january/2025/1/22/determining-essential-factors-required-for-expediting-neural-induction-of-precursors-to-retinal-organoids]
• 43. Production of clinical grade patient iPSC-derived 3D retinal ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04771-y]
• 44. Hyaluronan improves photoreceptor differentiation and ... [https://www.sciencedirect.com/science/article/pii/S1742706124002332]
• 45. Retinal organoid differentiation from iPSCs cultured in the ... [https://www.takarabio.com/learning-centers/stem-cell-research/technical-notes/organoids/retinal-organoid-differentiation-from-ipscs-cultured-in-the-cellartis-def-cs-500-culture-system?srsltid=AfmBOooGzeM1iq8LGkyeUCghgF3E9yN4F3raQ1Zi5fgLPCMq8A1kj0tj]
• 46. Retinal organoid chip: engineering a physiomimetic oxygen ... [https://pubs.rsc.org/en/content/articlehtml/2025/lc/d4lc00771a]
• 47. Improved Retinal Organoid Differentiation by Modulating ... [https://www.sciencedirect.com/science/article/pii/S2213671119303388]
• 48. Systematic Comparison of Retinal Organoid Differentiation ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6591558/]
• 49. Retinal Organoids: A Next-Generation Platform for High ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10837228/]
• 50. Hydrogel-based milliwell arrays for standardized and ... [https://www.nature.com/articles/s41598-020-67012-7]
• 51. Adaptive Optics Optical Coherence Tomography Analysis ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11331185/]
• 52. Generation of Retinal Organoids from Healthy and ... [https://www.jove.com/t/64509/generation-retinal-organoids-from-healthy-retinal-disease-specific]
• 53. Production of clinical grade patient iPSC-derived 3D retinal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12625545/]
• 54. Progress of iPSC-derived retinal organoids in the study of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12577290/]
• 55. Self-organization, quality control, and preclinical studies of ... [https://www.nature.com/articles/s42003-023-04543-5]
• 56. Retinal Organoids Long-Term Functional Characterization ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8707055/]
• 57. Retinal Organoids: Cultivation, Differentiation, and ... [https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2021.638439/full]
• 58. Transcriptome-based molecular staging of human stem cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6857775/]
• 59. Improving reproducibility of differentially expressed genes ... [https://www.nature.com/articles/s41467-025-62579-z]
• 60. Simultaneous profiling of RNA isoforms and chromatin ... [https://www.nature.com/articles/s41467-024-52335-0]
• 61. Human Pluripotent Stem Cell-Derived Retinal Organoids [https://pmc.ncbi.nlm.nih.gov/articles/PMC11170113/]
• 62. Longitudinal scRNA-seq of retinal organoids derived from ... [https://www.nature.com/articles/s41597-025-05079-5]
• 63. Single-Cell Transcriptomic Profiling of Human Retinal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9645368/]
• 64. An alternative approach to produce versatile retinal ... [https://www.nature.com/articles/s41598-020-79651-x]
• 65. Retinal organoid light responsivity: current status and ... [https://www.sciencedirect.com/science/article/abs/pii/S1931524422001335]
• 66. Retinal organoids in disease modeling and drug discovery [https://www.sciencedirect.com/science/article/abs/pii/S0039625723001273]
• 67. Retinal organoids as models for development and diseases [https://pmc.ncbi.nlm.nih.gov/articles/PMC8557999/]
• 68. Update on Retinoblastoma Therapies - PMC - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC12299372/]
• 69. Retinoblastoma with MYCN Amplification Diagnosed from Cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11095586/]
• 70. Differentiating MYCN-amplified RB1 wild-type ... [https://www.nature.com/articles/s41598-024-76933-6]
• 71. Human Retinal Organoid Modeling Defines Developmental ... [https://www.mdpi.com/1422-0067/26/17/8675]
• 72. A highly reproducible and efficient method for retinal organoid ... [https://scholars.uky.edu/en/publications/a-highly-reproducible-and-efficient-method-for-retinal-organoid-d/]